<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Acquired von Willebrand syndrome
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Acquired von Willebrand syndrome
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Acquired von Willebrand syndrome
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Paula James, MD, FRCPC
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Lawrence LK Leung, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Jennifer S Tirnauer, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Sep 14, 2022.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H429942366">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Inherited von Willebrand disease (VWD) is the most common inherited bleeding disorder. Acquired von Willebrand syndrome (AVWS; acquired deficiency or dysfunction of von Willebrand factor [VWF]) is much less common. Additionally, the diagnosis is not often suspected in a bleeding patient.
        </p>
        <p>
         AVWS can be caused by a number of underlying medical conditions, and bleeding symptoms in an individual with any of these diseases should raise suspicion and prompt an evaluation for AVWS. Evaluation and management may be complex, especially in those for whom the underlying disorder requires antithrombotic therapy, such as anticoagulation for a prosthetic heart valve or
         <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">
          aspirin
         </a>
         for essential thrombocythemia.
        </p>
        <p>
         This topic reviews the pathophysiology, evaluation, diagnosis, and management of AVWS. Inherited VWD and other causes of bleeding are discussed in separate topic reviews:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Inherited VWD
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Diagnosis and classification
         </strong>
         – (See
         <a class="medical medical_review" href="/z/d/html/1307.html" rel="external">
          "Clinical presentation and diagnosis of von Willebrand disease"
         </a>
         .)
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Major bleeding
         </strong>
         – (See
         <a class="medical medical_review" href="/z/d/html/1372.html" rel="external">
          "von Willebrand disease (VWD): Treatment of major bleeding and major surgery"
         </a>
         .)
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Minor bleeding
         </strong>
         – (See
         <a class="medical medical_review" href="/z/d/html/122618.html" rel="external">
          "von Willebrand disease (VWD): Treatment of minor bleeding, use of DDAVP, and routine preventive care"
         </a>
         .)
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Gynecology and obstetrics
         </strong>
         – (See
         <a class="medical medical_review" href="/z/d/html/139017.html" rel="external">
          "von Willebrand disease (VWD): Gynecologic and obstetric considerations"
         </a>
         .)
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Pathophysiology
         </strong>
         – (See
         <a class="medical medical_review" href="/z/d/html/1309.html" rel="external">
          "Pathophysiology of von Willebrand disease"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Evaluation for suspected bleeding disorders
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Children
         </strong>
         – (See
         <a class="medical medical_review" href="/z/d/html/5936.html" rel="external">
          "Approach to the child with bleeding symptoms"
         </a>
         .)
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Adults
         </strong>
         – (See
         <a class="medical medical_review" href="/z/d/html/1367.html" rel="external">
          "Approach to the adult with a suspected bleeding disorder"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/16287.html" rel="external">
          "Easy bruising"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1953356673">
         <span class="h1">
          PATHOPHYSIOLOGY
         </span>
        </p>
        <p class="headingAnchor" id="H2439790629">
         <span class="h2">
          Role of VWF in hemostasis
         </span>
         <span class="headingEndMark">
          —
         </span>
         von Willebrand factor (VWF) is an extremely large glycoprotein that is synthesized in megakaryocytes and endothelial cells; it undergoes extensive post-translational processing. Dimeric subunits of VWF undergo multimerization, and the multimers are stored in (and released from) Weibel-Palade bodies in endothelial cells and alpha granules in platelets and megakaryocytes. The high molecular weight multimers are the most active in hemostasis. Several proteases can cleave VWF, including ADAMTS13 (and possibly other metalloproteinases), leukocyte-derived proteases, and plasmin. (See
         <a class="medical medical_review" href="/z/d/html/1309.html" rel="external">
          "Pathophysiology of von Willebrand disease", section on 'Initial description'
         </a>
         .)
        </p>
        <p>
         VWF contributes significantly to primary hemostasis by binding to platelet receptors and vascular subendothelial structures at sites of endothelial injury, where it forms an adhesive bridge between platelets and the endothelial surface and also forms adhesions between adjacent platelets, especially in areas of high shear  (
         <a class="graphic graphic_figure graphicRef81908" href="/z/d/graphic/81908.html" rel="external">
          figure 1
         </a>
         ) [
         <a href="#rid1">
          1,2
         </a>
         ]. High molecular weight VWF multimers provide multiple binding sites that can interact with platelets and the subendothelium; as a result, they are the most active functional forms of VWF. (See
         <a class="medical medical_review" href="/z/d/html/1371.html" rel="external">
          "Overview of hemostasis", section on 'Formation of the platelet plug'
         </a>
         .)
        </p>
        <p>
         VWF also acts as a protective carrier protein for coagulation factor VIII and thus contributes to fibrin clot formation by maintaining factor VIII levels. In individuals with severe VWF deficiency, factor VIII levels can be as low as those in patients with moderate hemophilia A [
         <a href="#rid3">
          3
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/1309.html" rel="external">
          "Pathophysiology of von Willebrand disease", section on 'VWF functions'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3598497281">
         <span class="h2">
          Mechanisms of reduced VWF
         </span>
         <span class="headingEndMark">
          —
         </span>
         Mechanisms of reduced VWF activity in AVWS include immune and non-immune mechanisms  (
         <a class="graphic graphic_table graphicRef54202" href="/z/d/graphic/54202.html" rel="external">
          table 1
         </a>
         ) [
         <a href="#rid4">
          4-11
         </a>
         ]. Analysis of the multimeric structure of the patient's VWF often shows a decrease in the high molecular weight multimers in both immune and non-immune types of mechanisms [
         <a href="#rid10">
          10,12,13
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Antibody-mediated decrease
         </strong>
         – Immune-mediated reduction of VWF (eg, by autoantibodies to the VWF protein) may occur in monoclonal gammopathies, lymphoid neoplasms, and autoimmune diseases [
         <a href="#rid10">
          10,14,15
         </a>
         ]. The first case of AVWS was described in a teenager with systemic lupus erythematosus (SLE) [
         <a href="#rid16">
          16
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Many cases of immune-mediated AVWS do not have detectable inhibitory antibodies demonstrated by using mixing studies (assays of platelet-dependent VWF function); however, the absence of detectable autoantibodies does not eliminate the possibility of AVWS due to antibody-mediated enhanced VWF clearance [
         <a href="#rid17">
          17
         </a>
         ]. Some antibodies may have a higher affinity for larger multimers and possibly lead to a more selective clearance of high molecular weight (HMW) forms.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Autoantibodies that interfere with VWF function often lead to more serious bleeding [
         <a href="#rid15">
          15
         </a>
         ]. In a 1998 series of 25 patients with AVWS of different causes, those with a detectable autoantibody had a greater frequency of bleeding than those without a functionally detectable autoantibody (6 of 8 versus 1 of 16 [75 versus 6 percent]) [
         <a href="#rid10">
          10
         </a>
         ]. (See
         <a class="local">
          'Lymphoproliferative disorders'
         </a>
         below and
         <a class="local">
          'SLE and other autoimmune disorders'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Shear stress-induced proteolysis
         </strong>
         – The multimeric structure of VWF makes the protein sensitive to changes in fluid flow and shear stress, and in the normal circulation, VWF tumbles and undergoes oscillatory force cycles every few milliseconds. In areas of high shear stress, VWF multimers become unfolded and elongated, and are more susceptible to cleavage by ADAMTS13. Patients who have normal ADAMTS13 activity will have proteolysis of VWF in these circumstances.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         High levels of shear stress can occur with vessel stenosis (ventricular septal defect associated with certain congenital malformations, aortic stenosis, paravalvular leak after mitral valve replacement, hypertrophic obstructive cardiomyopathy) [
         <a href="#rid18">
          18-20
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Certain extracorporeal devices (eg, ECMO) and left ventricular assist devices (LVAD) can also produce extremely high shear stress and account for an increasing number of cases of AVWS [
         <a href="#rid21">
          21-23
         </a>
         ]. (See
         <a class="local">
          'Cardiovascular disease'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The levels of shear stress associated with these conditions (in Pascals [Pa]) have been reported to be as follows [
         <a href="#rid24">
          24
         </a>
         ]:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Normal veins – &lt;1 Pa
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Normal arteries and arterioles – 1 to 7 Pa
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Stenotic vessels – 4 to 45 Pa
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Centrifugal flow LVAD – approximately 200 Pa
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Axial flow LVAD – 600 Pa
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         However, not all patients with the shear stress conditions noted above have clinically significant bleeding, and LVAD and EMCO are also associated with a significant prothrombotic risk, suggesting that additional mechanisms may contribute to the hemostatic balance in these individuals. (See
         <a class="local">
          'Cardiovascular disease'
         </a>
         below and
         <a class="local">
          'Left ventricular assist device or extracorporeal membrane oxygenation'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Adsorption onto cells or proteins
         </strong>
         – VWF can be adsorbed onto cells (removing it from the circulation), and this may lead to increased clearance [
         <a href="#rid25">
          25,26
         </a>
         ]. This is a possible mechanism of AVWS in patients with Wilms tumor, Waldenström macroglobulinemia, and some non-Hodgkin lymphoma (NHL) and multiple myeloma patients [
         <a href="#rid27">
          27
         </a>
         ]. An aberrantly expressed platelet receptor for VWF, glycoprotein Ib (GPIb), has been reported on the cells in some patients with AVWS and a plasma cell dyscrasias [
         <a href="#rid27">
          27,28
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In patients with myeloproliferative neoplasms (MPNs), several reports have noted an inverse relationship between high platelet counts and the decrease of large VWF multimers, suggesting that adsorption of HMW VWF multimers onto platelets may cause reduced VWF levels; however, other mechanisms of VWF loss such as platelet activation, binding, and consequent proteolytic cleavage are also likely [
         <a href="#rid29">
          29-31
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Other proteases
         </strong>
         – Other proteases besides ADAMTS13 may contribute to VWF cleavage and reduction. As an example, states of excessive fibrinolysis such as disseminated intravascular coagulation (DIC), decompensated cirrhosis, and some cases of multiple myeloma have been associated with degradation of VWF, likely due to increased plasmin levels [
         <a href="#rid11">
          11,32
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Some patients with essential thrombocythemia (ET) also show evidence of increased VWF proteolysis, possibly due to released platelet metalloproteinases other than ADAMTS13 (as well as to ADAMTS13) [
         <a href="#rid31">
          31,33
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Decreased synthesis
         </strong>
         – Although uncommon, acquired reduction in VWF synthesis can occur in certain conditions such as hypothyroidism [
         <a href="#rid34">
          34,35
         </a>
         ]. (See
         <a class="local">
          'Hypothyroidism'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p>
         In some conditions, several mechanisms may coexist.
        </p>
        <p class="headingAnchor" id="H3458049758">
         <span class="h2">
          Consequences of reduced VWF
         </span>
         <span class="headingEndMark">
          —
         </span>
         The major complication of AVWS is an increased risk of bleeding. However, not all individuals with reduced VWF levels have increased bleeding [
         <a href="#rid21">
          21
         </a>
         ]. Bleeding occurs more often in patients who have VWF levels &lt;20 international units/dL. Those with levels of 20 to 30 international units/dL are at increased risk for bleeding, but there is no firm level that predicts bleeding. Other risk factors such as platelet dysfunction and medications may contribute to excessive bleeding in these patients. Patients with detectable inhibitory antibodies in mixing studies using platelet-dependent VWF activity have been noted to have more severe bleeding than those without inhibitory antibodies [
         <a href="#rid10">
          10
         </a>
         ]. (See
         <a class="local">
          'Mechanisms of reduced VWF'
         </a>
         above.)
        </p>
        <p>
         Mechanisms of increased bleeding risk in AVWS may include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Impaired platelet interactions
         </strong>
         – The most obvious and widely cited consequence of reduced VWF is impaired primary hemostasis due to reduced ability of platelets to interact with the subendothelium and other platelets. This may lead to mucosal bleeding and/or serious internal bleeding.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Reduced levels of plasma factor VIII
         </strong>
         – VWF acts as a carrier protein for factor VIII and increases factor VIII half-life substantially. In severe AVWS, decreased factor VIII may contribute to muscle or joint bleeding.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Angiodysplasia
         </strong>
         – VWF is thought to suppress angiogenesis; a direct causal association between AVWS and increased angiogenesis remains to be demonstrated [
         <a href="#rid36">
          36,37
         </a>
         ]. The increase in angiogenesis observed in some patients with AVWS may explain the common finding of bleeding from gastrointestinal angiodysplasia seen in some individuals with accompanying aortic stenosis or severe mitral regurgitation (Heyde syndrome) [
         <a href="#rid38">
          38
         </a>
         ]. (See
         <a class="local">
          'Aortic stenosis'
         </a>
         below and
         <a class="local">
          'Severe mitral regurgitation'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Potential mechanisms by which VWF controls angiogenesis may include changes in integrin-mediated adhesion and vascular endothelial growth factor receptor (VEGF) signalling, which in turn may alter several stages of blood vessel development and maturation [
         <a href="#rid37">
          37,39
         </a>
         ]. The likelihood of angiodysplasia in patients with von Willebrand disease has been estimated to be approximately 12 percent, although some reports suggest a lower frequency [
         <a href="#rid40">
          40,41
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Antithrombotic therapies
         </strong>
         – Some individuals with AVWS may also receive antiplatelet agents or anticoagulants, which may further increase bleeding risk. (See
         <a class="local">
          'Patients who require antithrombotic therapy'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2456594978">
         <span class="h1">
          EPIDEMIOLOGY
         </span>
         <span class="headingEndMark">
          —
         </span>
         AVWS is less common than inherited von Willebrand disease (VWD). In a 1993 international survey sent to 300 medical centers (4503 patients with VWD) asking for the distribution of VWD cases between inherited and acquired forms, only 1.2 percent were acquired [
         <a href="#rid40">
          40
         </a>
         ]. Other sources have quoted slightly higher ratios (approximately 5 percent in the Mayo Clinic experience) [
         <a href="#rid6">
          6,42
         </a>
         ].
        </p>
        <p>
         The true prevalence of AVWS is unknown, since many cases may be clinically silent or mild and remain undiagnosed [
         <a href="#rid33">
          33
         </a>
         ]. Over 700 cases have been reported in the literature [
         <a href="#rid43">
          43
         </a>
         ]. Underreporting is likely because testing is not routinely performed for individuals who are not bleeding. An estimated prevalence of up to 0.04 percent (1 in 2500) has been quoted based on a review of the Mayo Clinic database [
         <a href="#rid42">
          42
         </a>
         ].
        </p>
        <p>
         The prevalence of AVWS may be much higher in certain populations:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Lymphoproliferative disorders – Unknown. However, these diseases are one of the most common associated diseases reported in series of patients with AVWS. (See
         <a class="local">
          'Lymphoproliferative disorders'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Myeloproliferative neoplasms – 10 to 20 percent. (See
         <a class="local">
          'Myeloproliferative neoplasms including ET'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Autoimmune disorders – Unknown. (See
         <a class="local">
          'SLE and other autoimmune disorders'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Congenital cardiac anomalies or aortic stenosis – 10 to 70 percent. (See
         <a class="local">
          'Congenital heart disease'
         </a>
         below and
         <a class="local">
          'Aortic stenosis'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Left ventricular assist device (LVAD) or extracorporeal membrane oxygenation (ECMO) – Up to 100 percent. (See
         <a class="local">
          'Left ventricular assist device or extracorporeal membrane oxygenation'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Wilms tumor – 4 to 8 percent. (See
         <a class="local">
          'Wilms tumor'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2344655791">
         <span class="h1">
          ASSOCIATED DISEASES
         </span>
        </p>
        <p class="headingAnchor" id="H2065595599">
         <span class="h2">
          Overview of associated diseases
         </span>
         <span class="headingEndMark">
          —
         </span>
         AVWS may be diagnosed in a patient with a previously identified underlying cause  (
         <a class="graphic graphic_table graphicRef54202" href="/z/d/graphic/54202.html" rel="external">
          table 1
         </a>
         ), concurrently with the other diagnosis, or before the underlying cause has been identified.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Children
         </strong>
         – In children, the most common causes of AVWS include congenital heart disease, Wilms tumor, and autoimmunity [
         <a href="#rid44">
          44
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Adults
         </strong>
         – Common causes of AVWS in adults include autoimmune and lymphoproliferative disorders and cardiac conditions [
         <a href="#rid45">
          45
         </a>
         ]. In an international survey from 1993, all the adults with AVWS had a lymphoproliferative, myeloproliferative, or autoimmune disorder [
         <a href="#rid40">
          40
         </a>
         ]. However, the association between aortic stenosis and AVWS had not been well established at the time and was probably under-reported. The number of cases due to left ventricular assist devices (LVADs) or other devices that alter blood flow and cause high shear stress may be increasing and may comprise a larger number of cases of AVWS as these devices are used more frequently.
        </p>
        <p>
        </p>
        <p>
         Additional rare disorders associated with AVWS include amyloidosis, pesticide ingestion, viral and parasitic infections, glycogen storage disease, graft-versus-host disease (GVHD), systemic mastocytosis, and Ehlers-Danlos syndrome [
         <a href="#rid6">
          6,33,46
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H4225928837">
         <span class="h2">
          Vaccines
         </span>
         <span class="headingEndMark">
          —
         </span>
         One case of AVWS was described after COVID-19 vaccination in a patient with a previously unclear bleeding disorder who also had an acquired factor VIII inhibitor [
         <a href="#rid47">
          47
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2894615269">
         <span class="h2">
          Hematologic disorders
         </span>
        </p>
        <p class="headingAnchor" id="H4213051564">
         <span class="h3">
          Lymphoproliferative disorders
         </span>
         <span class="headingEndMark">
          —
         </span>
         Lymphoproliferative disorders and plasma cell dyscrasias associated with AVWS include monoclonal gammopathy of undetermined significance (MGUS), multiple myeloma (MM), Waldenström macroglobulinemia (WM), chronic lymphocytic leukemia (CLL), hairy cell leukemia, lymphosarcoma, and non-Hodgkin lymphoma (NHL) [
         <a href="#rid11">
          11,14,48-50
         </a>
         ]. In some cases, AVWS has been the presenting finding [
         <a href="#rid43">
          43
         </a>
         ].
        </p>
        <p>
         A 2000 report from an international VWD registry found lymphoproliferative disorders to be the most common cause of AVWS, representing 89 of 186 cases (48 percent) [
         <a href="#rid5">
          5
         </a>
         ]. In a 2003 report from a single institution that included 22 individuals with AVWS, 12 had a paraproteinemia, including six with MGUS, four with WM, one with MM, and one with NHL [
         <a href="#rid42">
          42
         </a>
         ]. The international registry report also conducted a literature review that found lymphoproliferative disorders accounted for approximately one-third; this lower frequency is likely due to reporting bias [
         <a href="#rid5">
          5
         </a>
         ].
        </p>
        <p>
         The likelihood of developing AVWS in an individual with a lymphoproliferative disorder is unknown, but given the high prevalence of the lymphoproliferative disorders, AVWS is probably a relatively uncommon complication. (See
         <a class="local">
          'Epidemiology'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H1473629499">
         <span class="h3">
          Myeloproliferative neoplasms including ET
         </span>
         <span class="headingEndMark">
          —
         </span>
         AVWS has been seen in all of the myeloproliferative neoplasms (MPNs); it is most commonly found in association with essential thrombocythemia (ET).
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Essential thrombocythemia
         </strong>
         <strong>
          (ET)
         </strong>
         – In a 2015 series of 170 consecutive patients with ET who had laboratory testing, AVWS was diagnosed in 34 (20 percent) [
         <a href="#rid51">
          51
         </a>
         ]. Features that correlated with AVWS in this study included younger age at the time of ET diagnosis (defined as &lt;56 years); greater frequency of bleeding symptoms; and higher red blood cell (RBC), monocyte, and platelet counts. Three-quarters of individuals with AVWS had platelet counts between 450,000 and 1,000,000/microL; three had platelet counts &gt;1 million/microL, and five had normal platelet counts. Most of the patients were diagnosed with AVWS within a few years of their ET diagnosis.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The high prevalence of AVWS in patients with ET, even those with modest thrombocytosis, raises important management considerations, as individuals with ET are at increased risk of thrombosis and may be treated with an antiplatelet agent such as
         <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">
          aspirin
         </a>
         to reduce this risk. Our approach to decision-making in these individuals is discussed below. (See
         <a class="local">
          'Patients who require antithrombotic therapy'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The mechanism of AVWS in individuals with ET is not fully understood, but evidence shows higher molecular weight multimers of VWF are often missing, suggesting increased proteolysis by platelet proteases may play a significant role. In some patients, the markedly increased numbers of platelets alone may bind a higher quantity of VWF, allowing VWF to unfold and become susceptible to ADAMTS13, the primary enzyme that cleaves VWF in the circulation [
         <a href="#rid31">
          31,51
         </a>
         ]. (See
         <a class="local">
          'Mechanisms of reduced VWF'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Polycythemia vera (PV)
         </strong>
         – In a 2015 series of 142 consecutive patients with PV who had testing of VWF levels, AVWS was identified in 17 (12 percent) [
         <a href="#rid52">
          52
         </a>
         ]. Features that correlated with AVWS in this group included younger age (age of PV diagnosis, 48 years in those with AVWS versus 60 years in those without); bleeding symptoms; higher RBC, white blood cell, and platelet counts; and lack of remission of PV.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Myelofibrosis
         </strong>
         – In a 2015 series of 32 consecutive patients with myelofibrosis (primary or secondary to another MPN) who had bleeding symptoms that prompted laboratory testing, AVWS was diagnosed in five (16 percent) [
         <a href="#rid53">
          53
         </a>
         ]. An additional 12 of 27 (44 percent) had bleeding for other reasons, emphasizing the need to evaluate these patients for other bleeding conditions.
        </p>
        <p>
        </p>
        <p>
         These studies did not identify any obvious predictors of which patients would develop AVWS. In the large series of patients with ET, the risk of AVWS was higher with higher platelet counts, but some patients had normal platelet counts, and there was no threshold platelet count that could be used to stratify risk [
         <a href="#rid51">
          51
         </a>
         ].
        </p>
        <p>
         We recommend testing for AVWS in any patient with MPN and bleeding, and we follow all patients with MPNs closely after the initiation of
         <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">
          aspirin
         </a>
         or other platelet inhibitory medications. Those receiving antiplatelet agents should have an evaluation for AVWS if they have bleeding or bruising. (See
         <a class="local">
          'Diagnostic evaluation'
         </a>
         below.)
        </p>
        <p>
         The mechanism of AVWS in these disorders may be multifactorial. (See
         <a class="local">
          'Mechanisms of reduced VWF'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H4188762860">
         <span class="h2">
          SLE and other autoimmune disorders
         </span>
         <span class="headingEndMark">
          —
         </span>
         The prevalence of AVWS in patients with systemic lupus erythematosus (SLE) or other autoimmune disorders has not been systematically evaluated. Case reports have described AVWS as the initial presentation of SLE or that preceded the diagnosis of SLE by one or more years [
         <a href="#rid45">
          45,54
         </a>
         ]. The mechanism is likely to involve autoantibody production. (See
         <a class="local">
          'Mechanisms of reduced VWF'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H3061961372">
         <span class="h2">
          Cardiovascular disease
         </span>
        </p>
        <p class="headingAnchor" id="H1382220264">
         <span class="h3">
          Congenital heart disease
         </span>
         <span class="headingEndMark">
          —
         </span>
         Studies in individuals with congenital heart disease have shown AVWS with a number of stenotic cardiovascular lesions; sometimes AVWS is not diagnosed until adulthood.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A 2016 study that evaluated for AVWS in 60 children with congenital aortic or pulmonary stenosis found evidence of the disease in seven (12 percent) [
         <a href="#rid55">
          55
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a 2014 series of 50 children with congenital heart disease who underwent cardiac catheterization or cardiac surgery, 26 had high-grade intracardiac or extracardiac stenoses [
         <a href="#rid56">
          56
         </a>
         ]. Significantly diminished VWF levels were documented in 13 of the 26 (50 percent); by comparison, none of the remaining 24 children without high grade stenosis had reduced VWF. None had major clinically significant bleeding, and surgical blood loss was similar between those with and without AVWS, suggesting AVWS was mild. In those with AVWS, the alterations in VWF resolved completely with surgical or interventional repair.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A 2014 study that included 192 adults with congenital heart disease found laboratory evidence of AVWS in 21 percent, with the highest prevalence in those with the most complex defects [
         <a href="#rid57">
          57
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3082633714">
         <span class="h3">
          Aortic stenosis
         </span>
         <span class="headingEndMark">
          —
         </span>
         AVWS is common in individuals with aortic stenosis (AS).
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a 2003 series of 42 consecutive adults with severe AS, nine (21 percent) had at least one episode of bleeding, most frequently from skin or mucosal sites [
         <a href="#rid58">
          58
         </a>
         ]. High molecular weight VWF multimers were reduced in 33 patients (79 percent)with severe AS; this resolved by day 1 after corrective valve surgery.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a 2015 series of 31 consecutive adults with severe AS, 21 (68 percent) had loss of large VWF multimers [
         <a href="#rid59">
          59
         </a>
         ]. There was a trend towards a correlation between the peak aortic gradient and the loss of large multimers, but there was no cutoff below which VWF was unaffected in this cohort. All of the individuals had a reduced hemoglobin level, with hemoglobin &lt;9 g/dL in 12 (39 percent). Endoscopy was performed in four, and in each case showed angiodysplasia. Seven of the patients with AVWS had aortic valve replacement, which resulted in resolution of AVWS in all cases.
        </p>
        <p>
        </p>
        <p>
         The association between aortic stenosis and bleeding from gastrointestinal angiodysplasia has been designated Heyde syndrome. In some cases this is attributed to AVWS, although some patients with the syndrome have normal VWF levels, and other mechanisms of angiodysplasia such as decreased gastrointestinal perfusion have been implicated [
         <a href="#rid60">
          60
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/8164.html" rel="external">
          "Clinical manifestations and diagnosis of aortic stenosis in adults", section on 'Bleeding tendency'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2460837643">
         <span class="h3">
          Severe mitral regurgitation
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with severe mitral regurgitation may develop AVWS by mechanisms identical to aortic stenosis, including Heyde syndrome [
         <a href="#rid61">
          61
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2399771871">
         <span class="h3">
          Left ventricular assist device or extracorporeal membrane oxygenation
         </span>
         <span class="headingEndMark">
          —
         </span>
         Left ventricular assist devices (LVAD) are mechanical circulatory devices used in patients with cardiogenic shock or end-stage heart failure. Extracorporeal membrane oxygenation (ECMO) devices are used to provide circulatory support, including during cardiac surgery. (See
         <a class="medical medical_review" href="/z/d/html/3459.html" rel="external">
          "Treatment of advanced heart failure with a durable mechanical circulatory support device"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1625.html" rel="external">
          "Extracorporeal life support in adults in the intensive care unit: Overview"
         </a>
         .)
        </p>
        <p>
         LVAD and ECMO can be associated with increased bleeding risk for several reasons, including the coagulopathic effect of extracorporeal circulation, anticoagulant therapy used to reduce the risk of pump thrombosis, platelet dysfunction, and shear stress induced by continuous flow across the device. The shear stress may damage VWF, and increased binding to platelets may enhance proteolysis by ADAMTS13 [
         <a href="#rid24">
          24
         </a>
         ]. (See
         <a class="local">
          'Mechanisms of reduced VWF'
         </a>
         above.)
        </p>
        <p>
         Bleeding within the first week after implantation is often attributed to mechanisms other than AVWS such as surgical bleeding or anticoagulation, but laboratory testing often shows that AVWS is also present at that time and may be an additional contributing factor [
         <a href="#rid24">
          24,62
         </a>
         ]. The changes in VWF resolve rapidly upon removal of the device.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          LVAD
         </strong>
         – The overall bleeding risk (from any cause) may be as high as 40 percent for some LVAD devices [
         <a href="#rid24">
          24
         </a>
         ]. All patients with continuous flow LVADs are assumed to have AVWS and are not routinely tested. However, only a small proportion of individuals with an LVAD have clinically significant bleeding due to AVWS [
         <a href="#rid24">
          24
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/87834.html" rel="external">
          "Management of long-term mechanical circulatory support devices", section on 'Bleeding'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          ECMO
         </strong>
         – In a 2015 series of 18 adults receiving ECMO, all had AVWS [
         <a href="#rid63">
          63
         </a>
         ]. Bleeding was often present, typically as diffuse mucosal or bronchial bleeding or bleeding at puncture sites. The VWF abnormalities were detectable within 24 hours of starting ECMO and resolved after removal of the device.
        </p>
        <p>
        </p>
        <p>
         As with other cardiovascular conditions, gastrointestinal bleeding may be seen with these devices. The frequency of gastrointestinal bleeding in patients with an LVAD has been estimated to be on the order of 17 to 30 percent, and up to one-third of this bleeding appears to be due to gastrointestinal angiodysplasia. (See
         <a class="local">
          'Consequences of reduced VWF'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H1417662718">
         <span class="h2">
          Wilms tumor
         </span>
         <span class="headingEndMark">
          —
         </span>
         Series of children with Wilms tumor have documented AVWS in four to eight percent [
         <a href="#rid64">
          64,65
         </a>
         ]. In the larger series, which included 185 children, all had resolution of the VWF abnormalities within two to four weeks of starting chemotherapy for the tumor [
         <a href="#rid64">
          64
         </a>
         ]. The authors reported that based on these findings they have initiated testing for AVWS in all patients with suspected Wilms tumor at their institution. We recommend testing for AVWS in any patient with Wilms tumor who has a bleeding history or who requires surgery or other invasive procedure. (See
         <a class="medical medical_review" href="/z/d/html/6237.html" rel="external">
          "Treatment and prognosis of Wilms tumor"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H548504700">
         <span class="h2">
          Hypothyroidism
         </span>
         <span class="headingEndMark">
          —
         </span>
         Hypothyroidism can cause AVWS, although the prevalence of AVWS in hypothyroidism is unknown and it appears to be uncommon. Most individuals are treated with thyroid hormone replacement and have resolution of the AVWS [
         <a href="#rid34">
          34,35
         </a>
         ].
        </p>
        <p>
         In a 2014 series of 90 consecutive adults with clinically overt untreated hypothyroidism, laboratory evidence of AVWS was present in 29 (32 percent) [
         <a href="#rid66">
          66
         </a>
         ]. Of these, 20 had some bleeding symptoms, which often included mild petechiae, bruises, or mucosal bleeding (epistaxis, oral bleeding, heavy menstrual bleeding). Most had moderate reductions in VWF:antigen and VWF:ristocetin cofactor levels (range, 10 to 50 percent). VWF levels correlated positively with the levels of free T4. The authors suggested that this prevalence is likely an overestimate since the cutoff for mild VWD using the 97.5 percentile will result in the inclusion of 2.5 percent or more of the general population.
        </p>
        <p>
         The main mechanism of AVWS in hypothyroidism is reduction of VWF synthesis in the setting of low thyroid hormone levels. Autoantibodies against VWF have also been reported in autoimmune thyroiditis [
         <a href="#rid48">
          48
         </a>
         ]. (See
         <a class="local">
          'Mechanisms of reduced VWF'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H2301487138">
         <span class="h2">
          Valproic acid and other medications
         </span>
         <span class="headingEndMark">
          —
         </span>
         Multiple medications have been implicated in causing AVWS, including
         <a class="drug drug_general" data-topicid="10035" href="/z/d/drug information/10035.html" rel="external">
          valproic acid
         </a>
         ,
         <a class="drug drug_general" data-topicid="9267" href="/z/d/drug information/9267.html" rel="external">
          ciprofloxacin
         </a>
         ,
         <a class="drug drug_general" data-topicid="8502" href="/z/d/drug information/8502.html" rel="external">
          griseofulvin
         </a>
         , hydroxyethyl starch (also called
         <a class="drug drug_general" data-topicid="8522" href="/z/d/drug information/8522.html" rel="external">
          hetastarch
         </a>
         ; used as a plasma expander) and dextrans [
         <a href="#rid6">
          6,67-70
         </a>
         ]. Their mechanisms are also diverse and include reduced synthesis (valproic acid), accelerated proteolysis (ciprofloxacin), and precipitation of the protein (hydroxyethyl starch) [
         <a href="#rid6">
          6
         </a>
         ]. (See
         <a class="local">
          'Mechanisms of reduced VWF'
         </a>
         above.)
        </p>
        <p>
         In a group of 83 children taking
         <a class="drug drug_general" data-topicid="10035" href="/z/d/drug information/10035.html" rel="external">
          valproic acid
         </a>
         for epilepsy, 63 and 23 percent had a history of bleeding or a prolonged bleeding time, respectively [
         <a href="#rid70">
          70
         </a>
         ]. In those patients whose VWF was assessed, 83 and 66 percent had mild reductions in VWF antigen (VWF:Ag) and VWF ristocetin cofactor activity (VWF:RCo), respectively.
        </p>
        <p class="headingAnchor" id="H101230588">
         <span class="h1">
          TYPICAL PRESENTATIONS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The two major settings in which AVWS is suspected are in a patient with an underlying condition known to predispose them to having reduced VWF levels, and in an individual with new-onset unexplained bleeding, usually involving mucosal surfaces [
         <a href="#rid8">
          8
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Individual with a known associated condition
         </strong>
         – AVWS may present in any of a number of associated conditions  (
         <a class="graphic graphic_table graphicRef54202" href="/z/d/graphic/54202.html" rel="external">
          table 1
         </a>
         ) (see
         <a class="local">
          'Associated diseases'
         </a>
         above), either as a known underlying disorder, or, less commonly, as the presenting finding in the absence of another recognized illness.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         An international registry was created in 2000 and identified 186 new cases of AVWS, with the following distribution of associated conditions [
         <a href="#rid5">
          5
         </a>
         ]:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Lymphoproliferative disorders – 48 percent
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Cardiovascular disorders – 21 percent
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Myeloproliferative disorders – 15 percent
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Other cancers – 5 percent
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Immunologic disorders – 2 percent
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In a different international cohort of patients with AVWS in association with a lymphoproliferative, myeloproliferative, or autoimmune disorder, the median age of presentation was 69 years, consistent with the epidemiology of these underlying conditions [
         <a href="#rid40">
          40
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          New-onset unexplained bleeding
         </strong>
         – For a patient without an underlying condition known to cause AVWS, new onset of mucosal or skin bleeding raises the possibility of an acquired disorder or a mild hereditary disorder that was previously unappreciated [
         <a href="#rid45">
          45
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Children
         </strong>
         - Some of the disease associations found in adults are not common in children. The more usual causes for AVWS in children include congenital heart disease, autoimmune diseases, neoplasia (Wilms tumor), and hypothyroidism [
         <a href="#rid44">
          44
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2213910511">
         <span class="h1">
          DIAGNOSTIC EVALUATION
         </span>
         <span class="headingEndMark">
          —
         </span>
         The diagnosis of AVWS requires a thorough history and clinical assessment supplemented by laboratory tests [
         <a href="#rid71">
          71
         </a>
         ]. The best screening remains the patient's medical history, including personal and family history of abnormal bleeding and hemostatic challenges. A personal history for underlying conditions known to cause AVWS should also be obtained, as well as a history of any medications that might cause bleeding.
        </p>
        <p>
         If the patient is bleeding, it may be necessary to intervene before the diagnostic evaluation has been completed. An antifibrinolytic agent may be given in some cases even if the underlying cause of bleeding has not been identified, since these agents work independently of a specific coagulation factor or platelet disorder. (See
         <a class="local">
          'Treatment of acute bleeding'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H1205520081">
         <span class="h2">
          Laboratory testing
         </span>
         <span class="headingEndMark">
          —
         </span>
         A complete blood count (CBC) with platelet count and coagulation testing including a prothrombin time (PT) and an activated partial thromboplastin time (aPTT) should be obtained if they are not already available.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          CBC, PT, and aPTT
         </strong>
         – In an individual with AVWS, the aPTT may be prolonged due to low factor VIII levels (see
         <a class="local">
          'Consequences of reduced VWF'
         </a>
         above); however, a normal aPTT does not eliminate the possibility of AVWS, because this test becomes prolonged only when the factor VIII level is below approximately 20 to 30 percent, depending on the laboratory. The platelet count and PT are unaffected in AVWS (although the platelet count may be abnormal due to an associated condition).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          VWF levels
         </strong>
         – VWF levels are appropriate in individuals with a high suspicion of AVWS based on clinical findings or screening laboratory results, especially if there is bleeding or need for a surgical procedure. This testing may also be appropriate for individuals with an MPN or other disorder before administration of
         <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">
          aspirin
         </a>
         or other platelet inhibitory drug, even if the individual does not have current bleeding. Additionally, patients with AVWS-associated diseases who will be treated with therapies that may reduce the platelet count below 40,000 to 50,000/microL should be evaluated for AVWS.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Since most patients with an LVAD or EMCO are considered to have AVWS of varying severity, it is not necessary to obtain VWF levels unless the patient has bleeding that is not explained by other possible causes, or if treatment for other possible causes of bleeding is not effective. If VWF levels are extremely low, this information should be incorporated into the treatment plan.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         We obtain the following tests:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         VWF antigen (VWF:Ag)
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Platelet-dependent VWF activity (VWF:RCo or VWF:GPIbM)
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Factor VIII activity (FVIII:C)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Additional details are presented separately. (See
         <a class="medical medical_review" href="/z/d/html/1307.html" rel="external">
          "Clinical presentation and diagnosis of von Willebrand disease", section on 'VWD screening tests'
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         Definitive reference ranges that specifically define AVWS have not been established. Most experts use the same cut-off values for AVWS and inherited VWD, and we consider this to be a reasonable approach.
        </p>
        <p>
         A number of factors may affect VWF measurements [
         <a href="#rid72">
          72-79
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         VWF is an acute phase reactant, increasing in the setting of physiologic stress or inflammation.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         VWF levels are affected by blood type. Type O individuals have plasma levels 25 to 30 percent lower than type A, B, or AB.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Estrogens increase VWF levels (eg, during pregnancy and use of oral hormonal contraceptives).
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Genetic polymorphisms in some populations (eg, African Americans) cause reduced VWF values in laboratory tests without affecting function.
        </p>
        <p>
        </p>
        <p>
         If the above tests are not definitive, further testing may be helpful:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         VWF multimers
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         VWF:propeptide
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         VWF:collagen binding
        </p>
        <p>
        </p>
        <p>
         Decreased collagen binding, decreased high molecular weight multimers (found in one-third or more of patients with AVWS), and/or a high ratio of VWF propeptide to VWF:Ag (eg, ratio &gt;2) may be found in patients with AVWS. The high VWF:propeptide to VWF:Ag ratio indicates increased clearance of VWF, which can be helpful in both the diagnosis and in confirming remission after treatment [
         <a href="#rid80">
          80
         </a>
         ]. While none of these tests is definitive for distinguishing AVWS from inherited VWD, they may at least help to establish the diagnosis of VWD and suggest the diagnosis of AVWS in the correct clinical setting. Other information may be more useful in distinguishing AVWS from inherited VWD, such as the response to initial treatment and a measurement of the half-life of infused VWF. (See
         <a class="local">
          'Distinguishing acquired from inherited disease'
         </a>
         below.)
        </p>
        <p>
         Results of testing for autoantibodies to VWF using functional tests (mixing studies) often are negative, even if such an antibody exists [
         <a href="#rid10">
          10,14,15
         </a>
         ]. This may be because the antibody is completely bound to the VWF protein (and hence not present in the plasma) or because the antibody decreases VWF levels by causing increased clearance of the VWF protein rather than inhibiting VWF function (and hence does not affect the results of the mixing study). If the mixing study is easily available, it is helpful when it is positive and therefore can be a reasonable option.
        </p>
        <p>
         A number of ELISA assays for autoantibodies to VWF have been developed in research laboratories, but none have been broadly standardized or widely used, and they are not widely available.
        </p>
        <p class="headingAnchor" id="H2562965666">
         <span class="h2">
          Distinguishing acquired from inherited disease
         </span>
         <span class="headingEndMark">
          —
         </span>
         Distinguishing AVWS from inherited VWD is important in planning treatment, especially if an intervention directed at AVWS such as immunosuppressive therapy is planned. Other reasons for distinguishing AVWS from inherited VWD include other treatment decisions, judgments about whether to search for an associated condition, and decisions about testing and counseling of relatives. (See
         <a class="local">
          'Post-diagnostic testing'
         </a>
         below and
         <a class="medical medical_review" href="/z/d/html/1372.html" rel="external">
          "von Willebrand disease (VWD): Treatment of major bleeding and major surgery"
         </a>
         .)
        </p>
        <p>
         There are no screening tests that distinguish congenital VWD from AVWS. For individuals with low VWF levels, findings that favor AVWS over congenital VWD include the following [
         <a href="#rid8">
          8
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Onset of bleeding later in life; history of prior uneventful surgery or trauma without excessive bleeding prior to bleeding episode(s)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Negative family history for VWD
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Presence of an inhibitor to VWF or VWF-binding antibodies
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Ratio of VWF:RCo to VWF:Ag &lt;0.7 and loss of high molecular weight (HMW) multimers (not always present; one must distinguish from VWD type 2A) [
         <a href="#rid81">
          81
         </a>
         ]
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Remission of bleeding after treatment of an underlying AVWS-associated disorder
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Response to treatment with intravenous
         <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">
          immune globulin
         </a>
         (IVIG), suggesting an IgG monoclonal gammopathy-associated AVWS
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Response to VWF-containing concentrates (usually short-lived) or
         <a class="drug drug_general" data-topicid="9330" href="/z/d/drug information/9330.html" rel="external">
          desmopressin
         </a>
        </p>
        <p>
        </p>
        <p>
         In cases in which it is difficult to determine whether VWD is acquired or inherited (children, or adults with an unclear bleeding history), there may be value in testing first degree relatives for VWD [
         <a href="#rid20">
          20
         </a>
         ]. The presence of VWD in first degree relatives is strongly suggestive of inherited disease.
        </p>
        <p class="headingAnchor" id="H3869464210">
         <span class="h2">
          Differential diagnosis
         </span>
         <span class="headingEndMark">
          —
         </span>
         The differential diagnosis of AVWS includes inherited VWD and other inherited and acquired bleeding disorders. Some of the conditions associated with AVWS are also associated with higher risks of other bleeding disorders.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Inherited VWD
         </strong>
         – Inherited VWD is the most common inherited bleeding disorder. Like AVWS, patients may have bleeding or bruising of variable severity. Like AVWS, reduced VWF levels and function are seen on laboratory testing, and several patterns of VWF multimers may be seen on multimer analysis. Unlike AVWS, in inherited VWD, some relatives are likely to be affected and to have similar laboratory abnormalities (except in cases of de novo mutations or uncertain parentage). Unlike AVWS, inherited VWD is due to genetic variations and thus does not respond to immunosuppressive therapies or treatments directed at reducing shear stress. (See
         <a class="medical medical_review" href="/z/d/html/1307.html" rel="external">
          "Clinical presentation and diagnosis of von Willebrand disease"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Other inherited bleeding disorders
         </strong>
         – Other inherited bleeding disorders include hemophilia (inherited deficiency of factor VIII [hemophilia A], factor IX [hemophilia B], or factor XI [hemophilia C]), rare deficiencies of other coagulation factors, hereditary hemorrhagic telangiectasia (HHT), and platelet disorders. Unlike AVWS, these disorders are associated with different laboratory abnormalities of coagulation and/or platelets rather than abnormal VWF levels or function.(See
         <a class="medical medical_review" href="/z/d/html/1310.html" rel="external">
          "Clinical manifestations and diagnosis of hemophilia"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1333.html" rel="external">
          "Factor XI (eleven) deficiency"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1336.html" rel="external">
          "Rare inherited coagulation disorders"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1345.html" rel="external">
          "Clinical manifestations and diagnosis of hereditary hemorrhagic telangiectasia (Osler-Weber-Rendu syndrome)"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Acquired inhibitors to other coagulation factors
         </strong>
         – Acquired factor inhibitors are autoantibodies to coagulation factors that interfere with hemostatic function. Autoantibodies to factor VIII are the most common acquired inhibitor. Like AVWS, acquired factor inhibitors may be seen in individuals with increased autoantibody production, such as systemic lupus erythematosus (SLE), other autoimmune disorders, and certain malignancies. Unlike AVWS, other acquired factor inhibitors are generally associated with a more severe prolongation of the aPTT or a prolongation of the PT (depending on the factor involved), a reduction of the involved specific factor level, usually evidence of a factor inhibitor on mixing studies, and normal levels of VWF. Although factor VIII may be decreased in AVWS, factor VIII function usually corrects in a factor VIII mixing study. (See
         <a class="medical medical_review" href="/z/d/html/1305.html" rel="external">
          "Acquired hemophilia A (and other acquired coagulation factor inhibitors)"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Platelet disorders
         </strong>
         – Acquired platelet disorders may occur in the setting of uremia, liver disease, and a number of medications. Inherited platelet disorders are uncommon. Like AVWS, platelet disorders may cause petechiae and mucosal bleeding with a normal platelet count. Unlike AVWS, these disorders do not alter VWF levels or function. (See
         <a class="medical medical_review" href="/z/d/html/6675.html" rel="external">
          "Inherited platelet function disorders (IPFDs)"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Antithrombotic therapies
         </strong>
         – Bleeding in a patient with any of the above conditions may be exacerbated by an antithrombotic agent (anticoagulant or anti-platelet agent). Like AVWS, patients receiving one of these agents may present with mucosal bleeding or soft tissue bleeding. Unlike AVWS, the antithrombotic therapies have predictable effects on coagulation and platelet testing, they do not affect VWF level or function, and the primary intervention for bleeding is to reverse and/or stop the drug. (See
         <a class="medical medical_review" href="/z/d/html/1348.html" rel="external">
          "Heparin and LMW heparin: Dosing and adverse effects"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1319.html" rel="external">
          "Fondaparinux: Dosing and adverse effects"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1370.html" rel="external">
          "Direct oral anticoagulants (DOACs) and parenteral direct-acting anticoagulants: Dosing and adverse effects"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1334.html" rel="external">
          "Warfarin and other VKAs: Dosing and adverse effects"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3899064269">
         <span class="h1">
          MANAGEMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         There are a number of management decisions to be made for patients with AVWS, including the selection of the best treatment for acute bleeding, the need for chronic (prophylactic) therapy, the role of treatment for the underlying condition, and the best way to manage individuals with AVWS who require antithrombotic therapy for their underlying disorder.
        </p>
        <p>
         Our approach discussed in the following sections is largely consistent with several review articles [
         <a href="#rid8">
          8,46,82,83
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1365633396">
         <span class="h2">
          Post-diagnostic testing
         </span>
         <span class="headingEndMark">
          —
         </span>
         There are no additional required tests in an individual diagnosed with AVWS. However, the following may be appropriate in selected individuals:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Evaluation of any abnormal findings on the complete blood count (CBC) and coagulation testing. This may include testing the levels of additional coagulation factors in the intrinsic pathway (factors IX and XI) when the presence of bleeding and prolongation of the activated aPTT is out of proportion to any observed decrease in the factor VIII level. Depending on the severity of bleeding, platelet function screening may also be undertaken. (See
         <a class="medical medical_review" href="/z/d/html/4433.html" rel="external">
          "Platelet function testing"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Evaluation for an underlying disorder associated with AVWS, if such a condition has not already been diagnosed [
         <a href="#rid8">
          8,71
         </a>
         ]. In many cases a thorough history and physical examination will be sufficient to identify one of the causative conditions described above. For those without a diagnosed associated condition, limited laboratory testing may include review of the CBC and blood smear for findings associated with hematologic disorders, thyroid stimulating hormone (TSH), and serum protein electrophoresis (SPEP) to detect monoclonal gammopathy, with subsequent testing guided by the results.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         If an associated condition is not identified, it may be appropriate to revisit the family history and/or test family members for inherited von Willebrand disease (VWD). (See
         <a class="medical medical_review" href="/z/d/html/1307.html" rel="external">
          "Clinical presentation and diagnosis of von Willebrand disease"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H222500770">
         <span class="h2">
          Treatment of acute bleeding
         </span>
         <span class="headingEndMark">
          —
         </span>
         The treatment of bleeding varies depending on its severity, the reversibility of the underlying cause, and other coexisting hemostatic abnormalities (for which appropriate treatment should be administered).
        </p>
        <p>
         For the most severe bleeding, von Willebrand factor (VWF) concentrates are used alone or in combination with other modalities; these are summarized in the table  (
         <a class="graphic graphic_table graphicRef129086" href="/z/d/graphic/129086.html" rel="external">
          table 2
         </a>
         ).
        </p>
        <p class="headingAnchor" id="H55671510">
         <span class="h3">
          Treatment of the underlying condition
         </span>
         <span class="headingEndMark">
          —
         </span>
         If possible, treat the underlying condition responsible for the AVWS. Conditions that lead to consumption or reduced half-life of VWF will also shorten the half-life of VWF concentrates and make them less effective at usual doses and intervals. However, for many of the conditions, treatment is not immediately possible, and it may take days to weeks to become effective if treatment is available. Thus, for clinically important bleeding, treatment of the underlying condition is important but must be accompanied by other therapies. The following may be appropriate in specific diseases:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Surgical correction for congenital heart defects or aortic stenosis.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Cytoreductive therapy for myeloproliferative neoplasms with very high platelet counts (eg, &gt;1 million).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Immunosuppressive therapy or intravenous
         <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">
          immune globulin
         </a>
         (IVIG) for conditions with autoantibodies to VWF such as SLE, monoclonal gammopathy of undetermined significance (MGUS), or chronic lymphocytic leukemia (CLL).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Plasmapheresis – Uncommonly, plasmapheresis has been used in cases with autoantibodies and serious bleeding to rapidly, though transiently, reduce antibody levels; this is most effective with IgM autoantibodies [
         <a href="#rid8">
          8
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Agents to treat angiodysplasia –
         <a class="drug drug_general" data-topicid="9714" href="/z/d/drug information/9714.html" rel="external">
          Octreotide
         </a>
         ,
         <a class="drug drug_general" data-topicid="10095" href="/z/d/drug information/10095.html" rel="external">
          thalidomide
         </a>
         ,
         <a class="drug drug_general" data-topicid="9822" href="/z/d/drug information/9822.html" rel="external">
          lenalidomide
         </a>
         , and
         <a class="drug drug_general" data-topicid="8949" href="/z/d/drug information/8949.html" rel="external">
          atorvastatin
         </a>
         have been used to treat gastrointestinal angiodysplasia in inherited VWD and should be useful in AVWS as well [
         <a href="#rid83">
          83
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1873881991">
         <span class="h3">
          Therapies for bleeding
         </span>
         <span class="headingEndMark">
          —
         </span>
         Specific treatments used initially for active bleeding associated with AVWS include DDAVP (
         <a class="drug drug_general" data-topicid="9330" href="/z/d/drug information/9330.html" rel="external">
          desmopressin
         </a>
         ) and VWF concentrates, alone or in combination  (
         <a class="graphic graphic_table graphicRef129086" href="/z/d/graphic/129086.html" rel="external">
          table 2
         </a>
         ).
        </p>
        <p class="headingAnchor" id="H929397864">
         <span class="h4">
          DDAVP
         </span>
         <span class="headingEndMark">
          —
         </span>
         The rationale for the use of DDAVP initially is that bleeding may respond rapidly to DDAVP without exposure to foreign proteins in VWF preparations, and DDAVP may be more readily available than VWF concentrates. Overall, the response rate is said to be approximately 30 percent, depending on the distribution of causes in any series of patients with AVWS [
         <a href="#rid33">
          33
         </a>
         ].
        </p>
        <p>
         DDAVP is usually avoided in individuals with cardiovascular disease and/or a history of thrombosis, as well as older, fragile patients who may be at high risk for thrombosis.
        </p>
        <p>
         Treatment with DDAVP may be rapidly effective, and it has the theoretical advantage over VWF concentrates of causing a transient release of ultrahigh molecular weight, very prothrombotic VWF multimers [
         <a href="#rid20">
          20
         </a>
         ].DDAVP is often administered when VWF concentrates are not immediately available. DDAVP should not be used (or used with great caution) in patients with a high risk of thrombosis [
         <a href="#rid20">
          20
         </a>
         ].
        </p>
        <p>
         DDAVP is given every 12 to 24 hours for a maximum of three doses; it should be administered intravenously for active bleeding in a newly diagnosed AVWS patient. It can be administered intranasally, subcutaneously, or intravenously  (
         <a class="graphic graphic_table graphicRef110532" href="/z/d/graphic/110532.html" rel="external">
          table 3
         </a>
         ) once the patient has been shown to have a sufficient increase in VWF and factor VIII activity levels after the initial intravenous administration. (See
         <a class="medical medical_review" href="/z/d/html/122618.html" rel="external">
          "von Willebrand disease (VWD): Treatment of minor bleeding, use of DDAVP, and routine preventive care", section on 'DDAVP'
         </a>
         .)
        </p>
        <p>
         With rare exceptions, these patients will not have been given a DDAVP trial in the non-bleeding state, but the first administration of DDAVP in this setting acts as a therapeutic trial; if the patient does not have a satisfactory response, no further doses of DDAVP are given. Tachyphylaxis occurs with DDAVP after the initial three to five doses of administration; for this reason and because of side effects, it is not generally used beyond three to five days in a given treatment session.
        </p>
        <p>
         DDAVP can cause hyponatremia, which can be severe and can lead to seizures. Serum sodium levels should be monitored with repeated doses, and free water intake should be limited.
        </p>
        <p>
         The efficacy of DDAVP depends on the cause of AVWS. In a study that compared the efficacy of DDAVP in 25 individuals with AVWS due to different underlying conditions, DDAVP was effective in correcting VWF levels in 15 of 16 patients without an autoantibody to VWF and in only 4 of 8 with an autoantibody to VWF [
         <a href="#rid10">
          10
         </a>
         ].
        </p>
        <p>
         DDAVP may be administered in addition to VWF concentrates, if the patient first receives a VWF concentrate and the VWF concentrate fails to sufficiently stop the bleeding.
        </p>
        <p class="headingAnchor" id="H3928830044">
         <span class="h4">
          VWF concentrates
         </span>
         <span class="headingEndMark">
          —
         </span>
         For clinically significant bleeding, VWF concentrates are administered intravenously, either after a poor response to a therapeutic trial with DDAVP (see
         <a class="local">
          'DDAVP'
         </a>
         above) or sometimes initially, depending on availability and circumstances.
        </p>
        <p>
         Plasma-derived and
         <a class="drug drug_general" data-topicid="105705" href="/z/d/drug information/105705.html" rel="external">
          recombinant VWF
         </a>
         products are available.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Dosing
         </strong>
         – A dose of
         <a class="drug drug_general" data-topicid="8782" href="/z/d/drug information/8782.html" rel="external">
          plasma-derived VWF
         </a>
         /FVIII concentrate of 40 to 60 international units per kg of body weight is given initially to attempt to reach a plasma level of 50 to 100 international units/dL.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Subsequent doses will depend on the response of the patient. Subsequent doses of 20 to 40 international units per kg of body weight every 12 hours usually maintains the plasma concentration at 50 to 100 percent in a patient without a shortened VWF half-life. Patients with AVWS may require higher and more frequent doses (eg, 50 to 100 international units/kg) to maintain desired VWF levels. The dose given is also dependent upon the degree of bleeding, as shown in the table  (
         <a class="graphic graphic_table graphicRef75956" href="/z/d/graphic/75956.html" rel="external">
          table 4
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Continuous infusion of factor has been used in a few patients whose factor levels cannot be maintained with intermittent infusions and who continue to bleed; the doses have varied between 2 and 15 international units per kg per hour [
         <a href="#rid84">
          84-86
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2732490488">
         <span class="h4">
          Recombinant VWF (rVWF)
         </span>
         <span class="headingEndMark">
          —
         </span>
         rVWF treatment for AVWS has shown good results, although there is not widespread experience. Theoretically it may be very useful due to its longer half-life, lack of factor VIII content (for patients who may already have high factor VIII levels), and inclusion of ultra-high molecular weight multimers [
         <a href="#rid87">
          87
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Monitoring
         </strong>
         – It is important to obtain levels of VWF and factor VIII activity immediately before and following infusion to determine the half-life of the infused products. Post-infusion levels can be measured at 4, 8, and 12 hours after the first infusion to obtain half-life information, with less frequent testing performed subsequently (every twelve hours or once daily) depending on the patient's clinical status.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In general, the goal is to maintain the activity of factor VIII and of VWF (generally measured as VWF:RCo or VWF:GPIbM) between 50 to 100 percent for 3 to 14 days for more serious bleeding or major surgery. Factor VIII activity should be monitored to ensure that it does not rise above 200 international units/dL, which increases the risk of thrombosis.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Supporting data
         </strong>
         – An in vitro study comparing rVWF and
         <a class="drug drug_general" data-topicid="8782" href="/z/d/drug information/8782.html" rel="external">
          plasma-derived VWF
         </a>
         concentrate indicated that rVWF yields higher levels of VWF activity and antigen and does not result in an increase in endogenous thrombin potential as the plasma-derived concentrate did [
         <a href="#rid88">
          88
         </a>
         ]. The usual starting dose is 80 international units/kg intravenously. Examples of successful use of rVWF include a pediatric patient with AVWS who had a good response and a patient with an IgM paraproteinemia who had a good response [
         <a href="#rid89">
          89,90
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Additional information about available VWF products and their administration is discussed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/1372.html" rel="external">
          "von Willebrand disease (VWD): Treatment of major bleeding and major surgery", section on 'VWF concentrates for major bleeding'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1383594045">
         <span class="h4">
          Antifibrinolytic therapy and topical agents
         </span>
         <span class="headingEndMark">
          —
         </span>
         Bleeding can also be treated with antifibrinolytic agents, especially bleeding from mucosal sites such as epistaxis, dental bleeding, or heavy menstrual bleeding.
        </p>
        <p>
         Available agents include
         <a class="drug drug_general" data-topicid="10011" href="/z/d/drug information/10011.html" rel="external">
          tranexamic acid
         </a>
         and
         <a class="drug drug_general" data-topicid="8561" href="/z/d/drug information/8561.html" rel="external">
          aminocaproic acid
         </a>
         .
        </p>
        <p>
         Topical agents such as Gelfoam or Surgicel soaked in
         <a class="drug drug_general" data-topicid="10285" href="/z/d/drug information/10285.html" rel="external">
          topical thrombin
         </a>
         can be used for nasal or oral bleeding. The antifibrinolytic and topical medications are frequently used in conjunction with other therapies for AVWS. Administration is similar to other bleeding conditions. (See
         <a class="medical medical_review" href="/z/d/html/94788.html" rel="external">
          "Management of bleeding in patients receiving direct oral anticoagulants", section on 'Antifibrinolytics and other pro-hemostatic therapies'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/122618.html" rel="external">
          "von Willebrand disease (VWD): Treatment of minor bleeding, use of DDAVP, and routine preventive care", section on 'Antifibrinolytic agents'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1688402487">
         <span class="h4">
          Recombinant activated factor VII (rFVIIa)
         </span>
         <span class="headingEndMark">
          —
         </span>
         Case reports have described the successful use of rFVIIa in patients with AVWS who have life-threatening bleeding not controlled by other measures [
         <a href="#rid91">
          91-93
         </a>
         ].
        </p>
        <p>
         rFVIIa does not raise VWF or factor VIII levels, but in cases of extreme or life-threatening bleeding that cannot be controlled by other means, it has been effective. (See
         <a class="medical medical_review" href="/z/d/html/1372.html" rel="external">
          "von Willebrand disease (VWD): Treatment of major bleeding and major surgery", section on 'Refractory bleeding'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1256326469">
         <span class="h4">
          IVIG
         </span>
         <span class="headingEndMark">
          —
         </span>
         Intravenous
         <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">
          immune globulin
         </a>
         (IVIG) is effective in some cases of AVWS, especially those due to anti-VWF autoantibodies  (
         <a class="graphic graphic_table graphicRef129086" href="/z/d/graphic/129086.html" rel="external">
          table 2
         </a>
         ); this often applies to patients with associated diseases such as SLE, monoclonal gammopathies such as MGUS, multiple myeloma, and some lymphoproliferative disorders [
         <a href="#rid10">
          10,33,94,95
         </a>
         ].
        </p>
        <p>
         In a report of 10 patients with AVWS due to MGUS,
         <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">
          IVIG
         </a>
         produced a more sustained response in VWF levels than VWF concentrates or DDAVP, and IVIG prevented perioperative bleeding [
         <a href="#rid96">
          96
         </a>
         ]. The benefits of IVIG in individuals with MGUS were mostly limited to those with IgG MGUS (not IgM MGUS).
        </p>
        <p>
         Dosing of
         <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">
          IVIG
         </a>
         is similar to that used in other autoimmune disorders (eg, 1 g/kg intravenously once daily for two days), and it is repeated at approximately three to four week intervals if needed [
         <a href="#rid33">
          33
         </a>
         ]. IVIG may be used in conjunction with VWF concentrates and/or DDAVP in patients with a suboptimal response to these medications [
         <a href="#rid33">
          33
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/4431.html" rel="external">
          "Overview of intravenous immune globulin (IVIG) therapy"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1798720310">
         <span class="h3">
          Therapies to decrease autoantibody levels
         </span>
         <span class="headingEndMark">
          —
         </span>
         The following may be appropriate in addition to therapies listed above:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Immunosuppressive therapy
         </strong>
         – Immunosuppressive therapy may be useful for reducing autoantibody production in individuals with disorders associated with autoantibodies to VWF. Besides glucocorticoids, this may include
         <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">
          cyclophosphamide
         </a>
         or other immune modifying medications, including the monoclonal antibody
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          rituximab
         </a>
         , which targets B cells [
         <a href="#rid94">
          94,97
         </a>
         ]. A 2016 case report described effective use of
         <a class="drug drug_general" data-topicid="9822" href="/z/d/drug information/9822.html" rel="external">
          lenalidomide
         </a>
         in two patients with AVWS, one due to MGUS and one to smoldering myeloma [
         <a href="#rid43">
          43
         </a>
         ]. Both had bleeding that did not respond to other therapies such as VWF concentrates and DDAVP, and both had a sustained response to lenalidomide, even after the dose was reduced or the drug discontinued. Consultation with a specialist in rheumatologic disorders or hematologic malignancies may be indicated.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Plasmapheresis
         </strong>
         – Plasmapheresis is used to remove autoantibodies on a temporary basis and is particularly helpful in patients with IgM autoantibodies.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2933838836">
         <span class="h3">
          Reversal of anticoagulation or antiplatelet therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Individuals with AVWS who develop clinically important bleeding while they are being treated with an anticoagulant or an antiplatelet agent may require reduction or reversal of anticoagulation. For those receiving antiplatelet agents, platelet transfusion may be appropriate for serious bleeding. (See
         <a class="medical medical_review" href="/z/d/html/1348.html" rel="external">
          "Heparin and LMW heparin: Dosing and adverse effects", section on 'Reversal'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1324.html" rel="external">
          "Management of warfarin-associated bleeding or supratherapeutic INR"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7918.html" rel="external">
          "Platelet transfusion: Indications, ordering, and associated risks", section on 'Antiplatelet agents'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2790612699">
         <span class="h3">
          Treatment of bleeding associated with gastrointestinal angiodysplasia
         </span>
         <span class="headingEndMark">
          —
         </span>
         Bleeding from gastrointestinal angiodysplasia can occur in patients with AVWS (see
         <a class="local">
          'Consequences of reduced VWF'
         </a>
         above). Management can be challenging, and high quality evidence is lacking to support a specific approach. The following may be appropriate in selected patients, with the choice among them individualized according to the individual's underlying medical condition(s) and the site(s) and severity of bleeding:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Local endoscopic procedures or embolization if the number of lesions and anatomy are amenable. (See
         <a class="medical medical_review" href="/z/d/html/2557.html" rel="external">
          "Angiodysplasia of the gastrointestinal tract", section on 'Treatment'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Systemic VWF therapies such as those described above, especially if lesions are more numerous or anatomically inaccessible [
         <a href="#rid36">
          36
         </a>
         ]. In some cases, prophylaxis with VWF concentrates may be effective, but higher doses at more frequent intervals might be needed (typical dose, 40 to 60 international units/kg intravenously two to three times per week). (See
         <a class="local">
          'Treatment of acute bleeding'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="10095" href="/z/d/drug information/10095.html" rel="external">
          Thalidomide
         </a>
         and its immunomodulatory (IMiD) derivatives. A 2015 report described the use of thalidomide in eight individuals with LVAD-associated AVWS and bleeding from gastrointestinal angiodysplasias [
         <a href="#rid62">
          62
         </a>
         ]. All treated patients had cessation of bleeding (five patients) or reduction in bleeding (two patients); one died of sepsis within one week of starting the drug.
         <a class="drug drug_general" data-topicid="9822" href="/z/d/drug information/9822.html" rel="external">
          Lenalidomide
         </a>
         and thalidomide have also been shown to be effective in the gastrointestinal angiodysplastic bleeding in inherited VWD and may be effective in AVWS [
         <a href="#rid83">
          83,98
         </a>
         ]. We would use this approach if other measures were ineffective. Contraindications to these medications must be taken into account.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          Rituximab
         </a>
         was used successfully to maintain remission in a 78-year-old male who had responded to
         <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">
          IVIG
         </a>
         for continuous bleeding from gastrointestinal angiodysplasia [
         <a href="#rid99">
          99
         </a>
         ]. He had received multiple other therapies, including
         <a class="drug drug_general" data-topicid="10095" href="/z/d/drug information/10095.html" rel="external">
          thalidomide
         </a>
         and local ablation, before IVIG and subsequently rituximab was administered.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="9714" href="/z/d/drug information/9714.html" rel="external">
          Octreotide
         </a>
         , a somatostatin analogue, has been used successfully in patients with AVWS and gastrointestinal bleeding [
         <a href="#rid100">
          100,101
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Statins, especially
         <a class="drug drug_general" data-topicid="8949" href="/z/d/drug information/8949.html" rel="external">
          atorvastatin
         </a>
         , may have antiangiogenic effects in some individuals. Case reports have described dramatic improvements with reduced transfusion requirements [
         <a href="#rid102">
          102,103
         </a>
         ]. A review that summarized the efficacy of various treatments for angiodysplasia identified 17 individuals treated with statins, with five (29 percent) reporting a good response [
         <a href="#rid104">
          104
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Once bleeding has been controlled, it is important to establish a plan for treating and preventing future bleeding.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H4045532543">
         <span class="h2">
          Bleeding prophylaxis and perioperative management
         </span>
         <span class="headingEndMark">
          —
         </span>
         The correlation between VWF levels and clinical bleeding is weak. Thus, decisions about prophylaxis and perioperative management should not be based solely on laboratory values but should also incorporate clinical features for each patient.
        </p>
        <p>
         Individuals with AVWS who require surgery should have a plan for prophylaxis and treatment of bleeding available to all clinicians involved in the patient's care. For elective surgery, delaying the procedure until the patient receives treatment of the underlying disorder causing AVWS may be the best approach. If this is not possible, hemostatic therapies as described above may be required  (
         <a class="graphic graphic_table graphicRef129086" href="/z/d/graphic/129086.html" rel="external">
          table 2
         </a>
         ), with the choice of agent and dosing dependent on the severity of the AVWS and the bleeding risk of the procedure. (See
         <a class="local">
          'Therapies for bleeding'
         </a>
         above.)
        </p>
        <p>
         In unusual cases, especially those in which definitive therapy for the underlying cause of AVWS is not undertaken, patients may require long-term prophylaxis against bleeding. An example is aortic stenosis with angiodysplasia (Heyde syndrome) in a patient who does not undergo aortic valve surgery [
         <a href="#rid36">
          36
         </a>
         ]. In such a patient, one might consider administering VWF concentrates two or three times weekly, following clinically for evidence of a change in the quantity of gastrointestinal blood loss.
        </p>
        <p>
         Specific prophylactic strategies for surgery follow:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         DDAVP can often be used successfully for minor procedures, as long as the patient has demonstrated a VWF response to a DDAVP test dose several days earlier (see
         <a class="local">
          'Post-diagnostic testing'
         </a>
         above). This should not be done in the one to two days before the procedure because there will be insufficient time for VWF stores to be replenished. The first perioperative dose of DDAVP is administered approximately one hour before the procedure, and subsequent doses can be given 6 to 12 hours after surgery and then every 24 hours. It is important for all patients to have VWF concentrates available in case DDAVP is ineffective. (See
         <a class="medical medical_review" href="/z/d/html/122618.html" rel="external">
          "von Willebrand disease (VWD): Treatment of minor bleeding, use of DDAVP, and routine preventive care", section on 'DDAVP'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         VWF concentrates are often required for major and high-bleeding-risk procedures. It is prudent to measure the response to VWF concentrates, including the half-life of the infused concentrate, the day before surgery if possible. The schedule and dosing is similar to that described above (see
         <a class="local">
          'Treatment of acute bleeding'
         </a>
         above), keeping in mind the possible use of continuous infusion.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Antifibrinolytic therapies may be especially useful for dental procedures and other procedures involving sites with high intrinsic fibrinolytic activity. Caution should be used in patients who have any danger of ureteral obstruction.
        </p>
        <p>
        </p>
        <p>
         Administration of these therapies is discussed in more detail above. (See
         <a class="local">
          'Treatment of acute bleeding'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H893307940">
         <span class="h2">
          Patients who require antithrombotic therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Management is especially challenging in patients with AVWS who also require antithrombotic therapy. Examples include those on a left ventricular assist device (LVAD) or extracorporeal membrane oxygenation (ECMO) device.
        </p>
        <p>
         Individuals who are not bleeding can be treated with anticoagulants judiciously. Common sense suggests that a short-acting agent that can be reversed should be used.
        </p>
        <p>
         If bleeding occurs, the risks and benefits of discontinuing anticoagulation are individualized according to the severity of bleeding and thromboembolic risk. Antithrombotic therapy should be discontinued for any serious or life-threatening bleeding; treatment with VWF concentrates may be appropriate (see
         <a class="local">
          'VWF concentrates'
         </a>
         above); and consideration should be given to removal of the LVAD or ECMO if possible.
        </p>
        <p class="headingAnchor" id="H679164708">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/119328.html" rel="external">
          "Society guideline links: Acquired bleeding disorders"
         </a>
         and
         <a class="medical medical_society_guidelines" href="/z/d/html/119323.html" rel="external">
          "Society guideline links: von Willebrand disease"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3825300158">
         <span class="h1">
          INFORMATION FOR PATIENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5
         <sup>
          th
         </sup>
         to 6
         <sup>
          th
         </sup>
         grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10
         <sup>
          th
         </sup>
         to 12
         <sup>
          th
         </sup>
         grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.
        </p>
        <p>
         Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Basics topics (see
         <a class="medical medical_basics" href="/z/d/html/15887.html" rel="external">
          "Patient education: von Willebrand disease (The Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Beyond the Basics topics (see
         <a class="medical medical_patient" href="/z/d/html/697.html" rel="external">
          "Patient education: von Willebrand disease (Beyond the Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2668350300">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Mechanisms
         </strong>
         – A number of conditions can reduce levels of von Willebrand factor (VWF) and cause acquired von Willebrand syndrome (AVWS). Mechanisms include autoantibodies to VWF, high shear with unfolding and subsequent cleavage of VWF (especially the most hemostatically active high molecular weight multimers), adsorption of VWF to cells, and decreased VWF production. (See
         <a class="local">
          'Pathophysiology'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Prevalence
         </strong>
         – The prevalence of AVWS is unknown, but it is likely to be 20- to 100-fold less common than heritable von Willebrand disease (VWD). The prevalence in certain disease populations is higher. (See
         <a class="local">
          'Epidemiology'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Causes
         </strong>
         – Major causes of AVWS include lymphoproliferative disorders, myeloproliferative disorders, autoimmune disorders, cardiovascular conditions with vessel stenosis or high flow, left ventricular assist device (LVAD), extracorporeal membrane oxygenation (EMCO), Wilms tumor, hypothyroidism, and certain medications  (
         <a class="graphic graphic_table graphicRef54202" href="/z/d/graphic/54202.html" rel="external">
          table 1
         </a>
         ). (See
         <a class="local">
          'Associated diseases'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Evaluation
         </strong>
         – AVWS may be suspected in a patient with a recognized associated underlying condition or with new-onset unexplained bleeding and no personal or family history of bleeding. A physical examination should focus on findings of associated conditions. Laboratory testing should include complete blood count (CBC), platelet count and screening coagulation testing. If the history and preliminary laboratory testing suggest AVWS, additional testing includes VWF antigen and activity and factor VIII activity. (See
         <a class="local">
          'Typical presentations'
         </a>
         above and
         <a class="local">
          'Laboratory testing'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         If an underlying cause is unknown, limited evaluation for possible hematologic disorders is appropriate (blood smear review, serum protein electrophoresis [SPEP]), as is testing for thyroid disease. Individuals not expected to have the underlying condition corrected soon may have a DDAVP test dose. (See
         <a class="local">
          'Post-diagnostic testing'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Differential
         </strong>
         – The differential diagnosis includes hereditary VWD, platelet abnormalities, and other hereditary bleeding disorders; acquired coagulation factor inhibitors; and effects of antithrombotic therapies. (See
         <a class="local">
          'Differential diagnosis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Management
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Bleeding
         </strong>
         – Treatment of acute bleeding may include treatment of the underlying condition and administration of DDAVP, VWF concentrates (plasma-derived or recombinant), antifibrinolytic and topical therapies, and/or others noted in the table  (
         <a class="graphic graphic_table graphicRef129086" href="/z/d/graphic/129086.html" rel="external">
          table 2
         </a>
         ) and discussed above. (See
         <a class="local">
          'Treatment of acute bleeding'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         Antithrombotic therapies may need to be discontinued in actively bleeding patients. Bypassing agents are rarely used. (See
         <a class="local">
          'Reversal of anticoagulation or antiplatelet therapy'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          IVIG and immunosuppression
         </strong>
         – Individuals with autoantibodies to VWF may be treated with intravenous
         <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">
          immune globulin
         </a>
         (IVIG) and may receive longer term benefit from immunosuppressive therapy. IVIG may be given concomitantly with other therapies. (See
         <a class="local">
          'Therapies to decrease autoantibody levels'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          GI lesions
         </strong>
         – Local or systemic therapies may be indicated depending on the number and anatomy of the lesions. (See
         <a class="local">
          'Treatment of bleeding associated with gastrointestinal angiodysplasia'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Perioperative
         </strong>
         – Prophylaxis against bleeding and perioperative management may comprise DDAVP, VWF concentrates, and/or
         <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">
          IVIG
         </a>
         , depending on the bleeding risk for the individual patient  (
         <a class="graphic graphic_table graphicRef129086" href="/z/d/graphic/129086.html" rel="external">
          table 2
         </a>
         ). (See
         <a class="local">
          'Bleeding prophylaxis and perioperative management'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Concurrent thrombotic risk
         </strong>
         – Some individuals may have an increased risk for thrombosis and may require antiplatelet therapy (essential thrombocythemia [ET]) or an anticoagulant (cardiovascular conditions). AVWS by itself is not a contraindication to these therapies, but close consultation with appropriate specialists regarding the timing of therapy, need for intensive monitoring, and available reversal strategies is advised. (See
         <a class="local">
          'Patients who require antithrombotic therapy'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p>
         <strong>
          ACKNOWLEDGMENT
         </strong>
         — The UpToDate editorial staff acknowledges Margaret E Rick, MD, who contributed to earlier versions of this topic review.
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Wagner DD. Cell biology of von Willebrand factor. Annu Rev Cell Biol 1990; 6:217.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ruggeri ZM, Ware J. von Willebrand factor. FASEB J 1993; 7:308.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brinkhous KM, Sandberg H, Garris JB, et al. Purified human factor VIII procoagulant protein: comparative hemostatic response after infusions into hemophilic and von Willebrand disease dogs. Proc Natl Acad Sci U S A 1985; 82:8752.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Veyradier A, Jenkins CS, Fressinaud E, Meyer D. Acquired von Willebrand syndrome: from pathophysiology to management. Thromb Haemost 2000; 84:175.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Federici AB, Rand JH, Bucciarelli P, et al. Acquired von Willebrand syndrome: data from an international registry. Thromb Haemost 2000; 84:345.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kumar S, Pruthi RK, Nichols WL. Acquired von Willebrand disease. Mayo Clin Proc 2002; 77:181.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Franchini M, Lippi G. Acquired von Willebrand syndrome: an update. Am J Hematol 2007; 82:368.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tiede A, Rand JH, Budde U, et al. How I treat the acquired von Willebrand syndrome. Blood 2011; 117:6777.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mohri H. Acquired von Willebrand syndrome: features and management. Am J Hematol 2006; 81:616.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mohri H, Motomura S, Kanamori H, et al. Clinical significance of inhibitors in acquired von Willebrand syndrome. Blood 1998; 91:3623.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dicke C, Schneppenheim S, Holstein K, et al. Distinct mechanisms account for acquired von Willebrand syndrome in plasma cell dyscrasias. Ann Hematol 2016; 95:945.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ball J, Malia RG, Greaves M, Preston FE. Demonstration of abnormal factor VIII multimers in acquired von Willebrand's disease associated with a circulating inhibitor. Br J Haematol 1987; 65:95.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tiede A, Priesack J, Werwitzke S, et al. Diagnostic workup of patients with acquired von Willebrand syndrome: a retrospective single-centre cohort study. J Thromb Haemost 2008; 6:569.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Handin RI, Martin V, Moloney WC. Antibody-induced von Willebrand's disease: a newly defined inhibitor syndrome. Blood 1976; 48:393.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           van Genderen PJ, Vink T, Michiels JJ, et al. Acquired von Willebrand disease caused by an autoantibody selectively inhibiting the binding of von Willebrand factor to collagen. Blood 1994; 84:3378.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Simone JV, Cornet JA, Abildgaard CF. Acquired von Willebrand's syndrome in systemic lupus erythematosus. Blood 1968; 31:806.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Federici AB, Budde U, Castaman G, et al. Current diagnostic and therapeutic approaches to patients with acquired von Willebrand syndrome: a 2013 update. Semin Thromb Hemost 2013; 39:191.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Blackshear JL, Schaff HV, Ommen SR, et al. Hypertrophic obstructive cardiomyopathy, bleeding history, and acquired von Willebrand syndrome: response to septal myectomy. Mayo Clin Proc 2011; 86:219.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gill JC, Wilson AD, Endres-Brooks J, Montgomery RR. Loss of the largest von Willebrand factor multimers from the plasma of patients with congenital cardiac defects. Blood 1986; 67:758.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Avila ML, Lee KJ, Bouskill V, et al. Acquired von Willebrand syndrome in paediatric patients with congenital heart disease: challenges in the diagnosis and management of this rare condition. Haemophilia 2015; 21:e89.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Heilmann C, Geisen U, Beyersdorf F, et al. Acquired von Willebrand syndrome in patients with extracorporeal life support (ECLS). Intensive Care Med 2012; 38:62.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Klovaite J, Gustafsson F, Mortensen SA, et al. Severely impaired von Willebrand factor-dependent platelet aggregation in patients with a continuous-flow left ventricular assist device (HeartMate II). J Am Coll Cardiol 2009; 53:2162.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tauber H, Ott H, Streif W, et al. Extracorporeal membrane oxygenation induces short-term loss of high-molecular-weight von Willebrand factor multimers. Anesth Analg 2015; 120:730.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nascimbene A, Neelamegham S, Frazier OH, et al. Acquired von Willebrand syndrome associated with left ventricular assist device. Blood 2016; 127:3133.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bracey AW, Wu AH, Aceves J, et al. Platelet dysfunction associated with Wilms tumor and hyaluronic acid. Am J Hematol 1987; 24:247.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Richard C, Cuadrado MA, Prieto M, et al. Acquired von Willebrand disease in multiple myeloma secondary to absorption of von Willebrand factor by plasma cells. Am J Hematol 1990; 35:114.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tefferi A, Hanson CA, Kurtin PJ, et al. Acquired von Willebrand's disease due to aberrant expression of platelet glycoprotein Ib by marginal zone lymphoma cells. Br J Haematol 1997; 96:850.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Scrobohaci ML, Daniel MT, Levy Y, et al. Expression of GpIb on plasma cells in a patient with monoclonal IgG and acquired von Willebrand disease. Br J Haematol 1993; 84:471.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           van Genderen PJ, Budde U, Michiels JJ, et al. The reduction of large von Willebrand factor multimers in plasma in essential thrombocythaemia is related to the platelet count. Br J Haematol 1996; 93:962.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fabris F, Casonato A, Grazia del Ben M, et al. Abnormalities of von Willebrand factor in myeloproliferative disease: a relationship with bleeding diathesis. Br J Haematol 1986; 63:75.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lancellotti S, Dragani A, Ranalli P, et al. Qualitative and quantitative modifications of von Willebrand factor in patients with essential thrombocythemia and controlled platelet count. J Thromb Haemost 2015; 13:1226.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Eikenboom JC, van der Meer FJ, Briët E. Acquired von Willebrand's disease due to excessive fibrinolysis. Br J Haematol 1992; 81:618.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Franchini M, Mannucci PM. Acquired von Willebrand syndrome: focused for hematologists. Haematologica 2020; 105:2032.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dalton RG, Dewar MS, Savidge GF, et al. Hypothyroidism as a cause of acquired von Willebrand's disease. Lancet 1987; 1:1007.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Michiels JJ, Budde U, van der Planken M, et al. Acquired von Willebrand syndromes: clinical features, aetiology, pathophysiology, classification and management. Best Pract Res Clin Haematol 2001; 14:401.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Franchini M, Mannucci PM. Von Willebrand disease-associated angiodysplasia: a few answers, still many questions. Br J Haematol 2013; 161:177.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Randi AM, Laffan MA. Von Willebrand factor and angiogenesis: basic and applied issues. J Thromb Haemost 2017; 15:13.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Onimoe G, Grooms L, Perdue K, Ruymann F. Acquired von Willebrand Syndrome in congenital heart disease: does it promote an increased bleeding risk? Br J Haematol 2011; 155:622.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Starke RD, Ferraro F, Paschalaki KE, et al. Endothelial von Willebrand factor regulates angiogenesis. Blood 2011; 117:1071.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fressinaud E, Meyer D. International survey of patients with von Willebrand disease and angiodysplasia. Thromb Haemost 1993; 70:546.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Castaman G, Di Bona E, Rodeghiero F. Angiodysplasia and von Willebrand's disease. Thromb Haemost 1994; 71:527.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kumar S, Pruthi RK, Nichols WL. Acquired von Willebrand's syndrome: a single institution experience. Am J Hematol 2003; 72:243.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lavin M, Brophy TM, Rawley O, et al. Lenalidomide as a novel treatment for refractory acquired von Willebrand syndrome associated with monoclonal gammopathy. J Thromb Haemost 2016; 14:1200.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Callaghan MU, Wong TE, Federici AB. Treatment of acquired von Willebrand syndrome in childhood. Blood 2013; 122:2019.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kasatkar P, Ghosh K, Shetty S. Acquired von Willebrand syndrome: a rare disorder of heterogeneous etiology. J Postgrad Med 2013; 59:98.
          </a>
         </li>
         <li class="breakAll">
          https://www.nhlbi.nih.gov/health-pro/guidelines/current/von-willebrand-guidelines (Accessed on February 06, 2017).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Portuguese AJ, Sunga C, Kruse-Jarres R, et al. Autoimmune- and complement-mediated hematologic condition recrudescence following SARS-CoV-2 vaccination. Blood Adv 2021; 5:2794.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Koyama T, Fujimoto K, Shima M. Acquired von Willebrand syndrome associated with Hashimoto's thyroiditis and subcutaneous mucosa-associated lymphoid tissue lymphoma. Intern Med 2013; 52:2661.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Alattar ML, Ciccone M, Gaballa MR, et al. Bleeding diathesis associated with acquired von Willebrand Syndrome in three patients with chronic lymphocytic leukemia. Leuk Lymphoma 2015; 56:3452.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Voisin S, Hamidou M, Lefrançois A, et al. Acquired von Willebrand syndrome associated with monoclonal gammopathy: a single-center study of 36 patients. Medicine (Baltimore) 2011; 90:404.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mital A, Prejzner W, Bieniaszewska M, Hellmann A. Prevalence of acquired von Willebrand syndrome during essential thrombocythemia: a retrospective analysis of 170 consecutive patients. Pol Arch Med Wewn 2015; 125:914.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mital A, Prejzner W, Świątkowska-Stodulska R, Hellmann A. Factors predisposing to acquired von Willebrand syndrome during the course of polycythemia vera - retrospective analysis of 142 consecutive cases. Thromb Res 2015; 136:754.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mital A, Prejzner W, Hellmann A. Acquired von Willebrand Syndrome During the Course of Myelofibrosis: Analysis of 32 Cases. Adv Clin Exp Med 2015; 24:1001.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stufano F, Baronciani L, Biguzzi E, et al. Severe acquired von Willebrand syndrome secondary to systemic lupus erythematosus. Haemophilia 2019; 25:e30.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Binnetoğlu FK, Babaoğlu K, Filiz ŞG, et al. Acquired von Willebrand syndrome in children with aortic and pulmonary stenosis. Cardiovasc J Afr 2016; 27:222.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Loeffelbein F, Funk D, Nakamura L, et al. Shear-stress induced acquired von Willebrand syndrome in children with congenital heart disease. Interact Cardiovasc Thorac Surg 2014; 19:926.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Waldow HC, Westhoff-Bleck M, Widera C, et al. Acquired von Willebrand syndrome in adult patients with congenital heart disease. Int J Cardiol 2014; 176:739.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vincentelli A, Susen S, Le Tourneau T, et al. Acquired von Willebrand syndrome in aortic stenosis. N Engl J Med 2003; 349:343.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tamura T, Horiuchi H, Imai M, et al. Unexpectedly High Prevalence of Acquired von Willebrand Syndrome in Patients with Severe Aortic Stenosis as Evaluated with a Novel Large Multimer Index. J Atheroscler Thromb 2015; 22:1115.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kapila A, Chhabra L, Khanna A. Valvular aortic stenosis causing angiodysplasia and acquired von Willebrand's disease: Heyde's syndrome. BMJ Case Rep 2014; 2014.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Blackshear JL, Wysokinska EM, Safford RE, et al. Shear stress-associated acquired von Willebrand syndrome in patients with mitral regurgitation. J Thromb Haemost 2014; 12:1966.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Draper K, Kale P, Martin B, et al. Thalidomide for treatment of gastrointestinal angiodysplasia in patients with left ventricular assist devices: case series and treatment protocol. J Heart Lung Transplant 2015; 34:132.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kalbhenn J, Schmidt R, Nakamura L, et al. Early diagnosis of acquired von Willebrand Syndrome (AVWS) is elementary for clinical practice in patients treated with ECMO therapy. J Atheroscler Thromb 2015; 22:265.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fosbury E, Szychot E, Slater O, et al. An 11-year experience of acquired von Willebrand syndrome in children diagnosed with Wilms tumour in a tertiary referral centre. Pediatr Blood Cancer 2017; 64.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Coppes MJ, Zandvoort SW, Sparling CR, et al. Acquired von Willebrand disease in Wilms' tumor patients. J Clin Oncol 1992; 10:422.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stuijver DJ, Piantanida E, van Zaane B, et al. Acquired von Willebrand syndrome in patients with overt hypothyroidism: a prospective cohort study. Haemophilia 2014; 20:326.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Aberg M, Hedner U, Bergentz SE. Effect of dextran on factor VIII (antihemophilic factor) and platelet function. Ann Surg 1979; 189:243.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sanfelippo MJ, Suberviola PD, Geimer NF. Development of a von Willebrand-like syndrome after prolonged use of hydroxyethyl starch. Am J Clin Pathol 1987; 88:653.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jonville-Béra AP, Autret-Leca E, Gruel Y. Acquired type I von Willebrand's disease associated with highly substituted hydroxyethyl starch. N Engl J Med 2001; 345:622.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kreuz W, Linde R, Funk M, et al. Valproate therapy induces von Willebrand disease type I. Epilepsia 1992; 33:178.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yawn B, Nichols WL, Rick ME. Diagnosis and management of von Willebrand disease: guidelines for primary care. Am Fam Physician 2009; 80:1261.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bellissimo DB, Christopherson PA, Flood VH, et al. VWF mutations and new sequence variations identified in healthy controls are more frequent in the African-American population. Blood 2012; 119:2135.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Flood VH, Gill JC, Morateck PA, et al. Common VWF exon 28 polymorphisms in African Americans affecting the VWF activity assay by ristocetin cofactor. Blood 2010; 116:280.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gill JC, Endres-Brooks J, Bauer PJ, et al. The effect of ABO blood group on the diagnosis of von Willebrand disease. Blood 1987; 69:1691.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           O'Donnell J, Boulton FE, Manning RA, Laffan MA. Genotype at the secretor blood group locus is a determinant of plasma von Willebrand factor level. Br J Haematol 2002; 116:350.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           van den Burg PJ, Hospers JE, van Vliet M, et al. Changes in haemostatic factors and activation products after exercise in healthy subjects with different ages. Thromb Haemost 1995; 74:1457.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McGill SN, Ahmed NA, Christou NV. Increased plasma von Willebrand factor in the systemic inflammatory response syndrome is derived from generalized endothelial cell activation. Crit Care Med 1998; 26:296.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           van der Poll T, van Deventer SJ, Pasterkamp G, et al. Tumor necrosis factor induces von Willebrand factor release in healthy humans. Thromb Haemost 1992; 67:623.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sié P, Caron C, Azam J, et al. Reassessment of von Willebrand factor (VWF), VWF propeptide, factor VIII:C and plasminogen activator inhibitors 1 and 2 during normal pregnancy. Br J Haematol 2003; 121:897.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lee A, Sinclair G, Valentine K, et al. Acquired von Willebrand syndrome: von Willebrand factor propeptide to von Willebrand factor antigen ratio predicts remission status. Blood 2014; 124:e1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Leebeek FWG. New Developments in Diagnosis and Management of Acquired Hemophilia and Acquired von Willebrand Syndrome. Hemasphere 2021; 5:e586.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nichols WL, Hultin MB, James AH, et al. von Willebrand disease (VWD): evidence-based diagnosis and management guidelines, the National Heart, Lung, and Blood Institute (NHLBI) Expert Panel report (USA). Haemophilia 2008; 14:171.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Biguzzi E, Siboni SM, Peyvandi F. How I treat gastrointestinal bleeding in congenital and acquired von Willebrand disease. Blood 2020; 136:1125.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Frank RD, Kunz D, Wirtz DC. Acquired von Willebrand disease--hemostatic management of major orthopedic surgery with high-dose immunoglobulin, desmopressin, and continuous factor concentrate infusion. Am J Hematol 2002; 70:64.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Patel SB, Rodgers GM. Continuous infusion of human plasma-derived von Willebrand factor concentrate as an effective therapy in a patient with acquired von Willebrand disease. Haemophilia 2014; 20:e411.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dane KE, Lindsley JP, Kickler T, et al. Continuous-infusion von Willebrand factor concentrate is effective for the management of acquired von Willebrand disease. Blood Adv 2021; 5:2813.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Erratum: Gill JC, Castaman G, Windyga J, et al. Hemostatic efficacy, safety, and pharmacokinetics of a recombinant von Willebrand factor in severe von Willebrand disease. Blood. 2015;126(17):2038-2046. Blood 2016; 127:2777.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mazzeffi M, Henderson R, Krause E, et al. In Vitro Comparison of Recombinant and Plasma-Derived von Willebrand Factor Concentrate for Treatment of Acquired von Willebrand Syndrome in Adult Extracorporeal Membrane Oxygenation Patients. Anesth Analg 2022; 134:312.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Weyand AC, Jesudas R, Pipe SW. Advantage of recombinant von Willebrand factor for peri-operative management in paediatric acquired von Willebrand syndrome. Haemophilia 2018; 24:e120.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Höpting M, Budde U, Tiede A, et al. Distinct Mechanisms of IgM Antibody-Mediated Acquired von Willebrand Syndrome and Successful Treatment with Recombinant von Willebrand Factor in One Patient. Acta Haematol 2022; 145:454.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Friederich PW, Wever PC, Briët E, et al. Successful treatment with recombinant factor VIIa of therapy-resistant severe bleeding in a patient with acquired von Willebrand disease. Am J Hematol 2001; 66:292.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Smaradottir A, Bona R. A case of acquired von Willebrand syndrome successfully treated with recombinant Factor VIIa during thyroidectomy. Thromb Haemost 2004; 92:666.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Franchini M, Veneri D, Lippi G. The use of recombinant activated factor VII in congenital and acquired von Willebrand disease. Blood Coagul Fibrinolysis 2006; 17:615.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Viallard JF, Pellegrin JL, Vergnes C, et al. Three cases of acquired von Willebrand disease associated with systemic lupus erythematosus. Br J Haematol 1999; 105:532.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sampson B, Anderson DR, Dugal M, et al. Acquired type 2a von Willebrand's disease: response to immunoglobulin infusion. Haemostasis 1997; 27:286.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Federici AB, Stabile F, Castaman G, et al. Treatment of acquired von Willebrand syndrome in patients with monoclonal gammopathy of uncertain significance: comparison of three different therapeutic approaches. Blood 1998; 92:2707.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kanakry JA, Gladstone DE. Maintaining hemostasis in acquired von Willebrand syndrome: a review of intravenous immunoglobulin and the importance of rituximab dose scheduling. Transfusion 2013; 53:1730.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Khatri NV, Patel B, Kohli DR, et al. Lenalidomide as a novel therapy for gastrointestinal angiodysplasia in von Willebrand disease. Haemophilia 2018; 24:278.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hawken J, Knott A, Alsakkaf W, et al. Rituximab to the rescue: novel therapy for chronic gastrointestinal bleeding due to angiodysplasia and acquired von Willebrand syndrome. Frontline Gastroenterol 2019; 10:434.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nakajima-Doi S, Seguchi O, Shintani Y, et al. Experience of the use of octreotide for refractory gastrointestinal bleeding in a patient with Jarvik2000® left ventricular assist device. J Artif Organs 2019; 22:334.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sieg AC, Moretz JD, Horn E, Jennings DL. Pharmacotherapeutic Management of Gastrointestinal Bleeding in Patients with Continuous-Flow Left Ventricular Assist Devices. Pharmacotherapy 2017; 37:1432.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Alikhan R, Keeling D. Von Willebrand disease, angiodysplasia and atorvastatin. Br J Haematol 2010; 149:159.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sohal M, Laffan M. Von Willebrand disease and angiodysplasia responding to atorvastatin. Br J Haematol 2008; 142:308.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chornenki NLJ, Shanjer M, James PD. Vascular abnormalities in patients with von Willebrand disease: A scoping review. J Thromb Haemost 2021; 19:2151.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 110531 Version 23.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2275814" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Cell biology of von Willebrand factor.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8440408" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : von Willebrand factor.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3936044" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Purified human factor VIII procoagulant protein: comparative hemostatic response after infusions into hemophilic and von Willebrand disease dogs.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10959686" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Acquired von Willebrand syndrome: from pathophysiology to management.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10959711" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Acquired von Willebrand syndrome: data from an international registry.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11838652" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Acquired von Willebrand disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17133419" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Acquired von Willebrand syndrome: an update.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21540459" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : How I treat the acquired von Willebrand syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16823821" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Acquired von Willebrand syndrome: features and management.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9572997" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Clinical significance of inhibitors in acquired von Willebrand syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27040683" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Distinct mechanisms account for acquired von Willebrand syndrome in plasma cell dyscrasias.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3101732" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Demonstration of abnormal factor VIII multimers in acquired von Willebrand's disease associated with a circulating inhibitor.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18208537" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Diagnostic workup of patients with acquired von Willebrand syndrome: a retrospective single-centre cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1085186" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Antibody-induced von Willebrand's disease: a newly defined inhibitor syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7949092" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Acquired von Willebrand disease caused by an autoantibody selectively inhibiting the binding of von Willebrand factor to collagen.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4172730" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Acquired von Willebrand's syndrome in systemic lupus erythematosus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23397553" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Current diagnostic and therapeutic approaches to patients with acquired von Willebrand syndrome: a 2013 update.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21364113" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Hypertrophic obstructive cardiomyopathy, bleeding history, and acquired von Willebrand syndrome: response to septal myectomy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3484979" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Loss of the largest von Willebrand factor multimers from the plasma of patients with congenital cardiac defects.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25495773" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Acquired von Willebrand syndrome in paediatric patients with congenital heart disease: challenges in the diagnosis and management of this rare condition.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21965100" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Acquired von Willebrand syndrome in patients with extracorporeal life support (ECLS).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19497443" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Severely impaired von Willebrand factor-dependent platelet aggregation in patients with a continuous-flow left ventricular assist device (HeartMate II).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25565317" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Extracorporeal membrane oxygenation induces short-term loss of high-molecular-weight von Willebrand factor multimers.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27143258" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Acquired von Willebrand syndrome associated with left ventricular assist device.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3030095" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Platelet dysfunction associated with Wilms tumor and hyaluronic acid.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2205095" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Acquired von Willebrand disease in multiple myeloma secondary to absorption of von Willebrand factor by plasma cells.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9074430" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Acquired von Willebrand's disease due to aberrant expression of platelet glycoprotein Ib by marginal zone lymphoma cells.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8217799" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Expression of GpIb on plasma cells in a patient with monoclonal IgG and acquired von Willebrand disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8703834" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : The reduction of large von Willebrand factor multimers in plasma in essential thrombocythaemia is related to the platelet count.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3085704" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Abnormalities of von Willebrand factor in myeloproliferative disease: a relationship with bleeding diathesis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25876231" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Qualitative and quantitative modifications of von Willebrand factor in patients with essential thrombocythemia and controlled platelet count.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1390254" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Acquired von Willebrand's disease due to excessive fibrinolysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32554559" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Acquired von Willebrand syndrome: focused for hematologists.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2883346" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Hypothyroidism as a cause of acquired von Willebrand's disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11686107" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Acquired von Willebrand syndromes: clinical features, aetiology, pathophysiology, classification and management.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23432086" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Von Willebrand disease-associated angiodysplasia: a few answers, still many questions.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27778439" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Von Willebrand factor and angiogenesis: basic and applied issues.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21569008" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Acquired von Willebrand Syndrome in congenital heart disease: does it promote an increased bleeding risk?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21048155" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Endothelial von Willebrand factor regulates angiogenesis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8259565" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : International survey of patients with von Willebrand disease and angiodysplasia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8052976" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Angiodysplasia and von Willebrand's disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12666134" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Acquired von Willebrand's syndrome: a single institution experience.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26991062" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Lenalidomide as a novel treatment for refractory acquired von Willebrand syndrome associated with monoclonal gammopathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23878141" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Treatment of acquired von Willebrand syndrome in childhood.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23793308" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Acquired von Willebrand syndrome: a rare disorder of heterogeneous etiology.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23793308" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Acquired von Willebrand syndrome: a rare disorder of heterogeneous etiology.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34255033" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Autoimmune- and complement-mediated hematologic condition recrudescence following SARS-CoV-2 vaccination.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24292759" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Acquired von Willebrand syndrome associated with Hashimoto's thyroiditis and subcutaneous mucosa-associated lymphoid tissue lymphoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25926060" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Bleeding diathesis associated with acquired von Willebrand Syndrome in three patients with chronic lymphocytic leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22033454" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Acquired von Willebrand syndrome associated with monoclonal gammopathy: a single-center study of 36 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26658493" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Prevalence of acquired von Willebrand syndrome during essential thrombocythemia: a retrospective analysis of 170 consecutive patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26269222" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Factors predisposing to acquired von Willebrand syndrome during the course of polycythemia vera - retrospective analysis of 142 consecutive cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26771972" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Acquired von Willebrand Syndrome During the Course of Myelofibrosis: Analysis of 32 Cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30408840" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Severe acquired von Willebrand syndrome secondary to systemic lupus erythematosus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27841910" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Acquired von Willebrand syndrome in children with aortic and pulmonary stenosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25228244" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Shear-stress induced acquired von Willebrand syndrome in children with congenital heart disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25139318" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Acquired von Willebrand syndrome in adult patients with congenital heart disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12878741" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Acquired von Willebrand syndrome in aortic stenosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26269004" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Unexpectedly High Prevalence of Acquired von Willebrand Syndrome in Patients with Severe Aortic Stenosis as Evaluated with a Novel Large Multimer Index.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24686797" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Valvular aortic stenosis causing angiodysplasia and acquired von Willebrand's disease: Heyde's syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25251907" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Shear stress-associated acquired von Willebrand syndrome in patients with mitral regurgitation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25447569" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Thalidomide for treatment of gastrointestinal angiodysplasia in patients with left ventricular assist devices: case series and treatment protocol.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25186021" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Early diagnosis of acquired von Willebrand Syndrome (AVWS) is elementary for clinical practice in patients treated with ECMO therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27616321" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : An 11-year experience of acquired von Willebrand syndrome in children diagnosed with Wilms tumour in a tertiary referral centre.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1311024" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Acquired von Willebrand disease in Wilms' tumor patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24118466" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Acquired von Willebrand syndrome in patients with overt hypothyroidism: a prospective cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/426556" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Effect of dextran on factor VIII (antihemophilic factor) and platelet function.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2445195" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Development of a von Willebrand-like syndrome after prolonged use of hydroxyethyl starch.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11529231" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Acquired type I von Willebrand's disease associated with highly substituted hydroxyethyl starch.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1733754" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Valproate therapy induces von Willebrand disease type I.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19961139" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Diagnosis and management of von Willebrand disease: guidelines for primary care.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22197721" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : VWF mutations and new sequence variations identified in healthy controls are more frequent in the African-American population.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20231421" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Common VWF exon 28 polymorphisms in African Americans affecting the VWF activity assay by ristocetin cofactor.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3495304" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : The effect of ABO blood group on the diagnosis of von Willebrand disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11841438" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : Genotype at the secretor blood group locus is a determinant of plasma von Willebrand factor level.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8772220" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : Changes in haemostatic factors and activation products after exercise in healthy subjects with different ages.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9468168" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : Increased plasma von Willebrand factor in the systemic inflammatory response syndrome is derived from generalized endothelial cell activation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1509401" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : Tumor necrosis factor induces von Willebrand factor release in healthy humans.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12786801" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : Reassessment of von Willebrand factor (VWF), VWF propeptide, factor VIII:C and plasminogen activator inhibitors 1 and 2 during normal pregnancy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24951428" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : Acquired von Willebrand syndrome: von Willebrand factor propeptide to von Willebrand factor antigen ratio predicts remission status.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34095769" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : New Developments in Diagnosis and Management of Acquired Hemophilia and Acquired von Willebrand Syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18315614" id="rid81" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          82 : von Willebrand disease (VWD): evidence-based diagnosis and management guidelines, the National Heart, Lung, and Blood Institute (NHLBI) Expert Panel report (USA).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32584960" id="rid82" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          83 : How I treat gastrointestinal bleeding in congenital and acquired von Willebrand disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11994985" id="rid83" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          84 : Acquired von Willebrand disease--hemostatic management of major orthopedic surgery with high-dose immunoglobulin, desmopressin, and continuous factor concentrate infusion.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25333342" id="rid84" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          85 : Continuous infusion of human plasma-derived von Willebrand factor concentrate as an effective therapy in a patient with acquired von Willebrand disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34269797" id="rid85" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          86 : Continuous-infusion von Willebrand factor concentrate is effective for the management of acquired von Willebrand disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31265496" id="rid86" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          87 : Erratum: Gill JC, Castaman G, Windyga J, et al. Hemostatic efficacy, safety, and pharmacokinetics of a recombinant von Willebrand factor in severe von Willebrand disease. Blood. 2015;126(17):2038-2046.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34903705" id="rid87" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          88 : In Vitro Comparison of Recombinant and Plasma-Derived von Willebrand Factor Concentrate for Treatment of Acquired von Willebrand Syndrome in Adult Extracorporeal Membrane Oxygenation Patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29418043" id="rid88" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          89 : Advantage of recombinant von Willebrand factor for peri-operative management in paediatric acquired von Willebrand syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35086107" id="rid89" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          90 : Distinct Mechanisms of IgM Antibody-Mediated Acquired von Willebrand Syndrome and Successful Treatment with Recombinant von Willebrand Factor in One Patient.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11279642" id="rid90" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          91 : Successful treatment with recombinant factor VIIa of therapy-resistant severe bleeding in a patient with acquired von Willebrand disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15457604" id="rid91" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          92 : A case of acquired von Willebrand syndrome successfully treated with recombinant Factor VIIa during thyroidectomy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17102646" id="rid92" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          93 : The use of recombinant activated factor VII in congenital and acquired von Willebrand disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10233433" id="rid93" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          94 : Three cases of acquired von Willebrand disease associated with systemic lupus erythematosus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9731109" id="rid94" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          95 : Acquired type 2a von Willebrand's disease: response to immunoglobulin infusion.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9763553" id="rid95" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          96 : Treatment of acquired von Willebrand syndrome in patients with monoclonal gammopathy of uncertain significance: comparison of three different therapeutic approaches.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23252513" id="rid96" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          97 : Maintaining hemostasis in acquired von Willebrand syndrome: a review of intravenous immunoglobulin and the importance of rituximab dose scheduling.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29446520" id="rid97" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          98 : Lenalidomide as a novel therapy for gastrointestinal angiodysplasia in von Willebrand disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31656571" id="rid98" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          99 : Rituximab to the rescue: novel therapy for chronic gastrointestinal bleeding due to angiodysplasia and acquired von Willebrand syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31338629" id="rid99" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          100 : Experience of the use of octreotide for refractory gastrointestinal bleeding in a patient with Jarvik2000®left ventricular assist device.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28833332" id="rid100" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          101 : Pharmacotherapeutic Management of Gastrointestinal Bleeding in Patients with Continuous-Flow Left Ventricular Assist Devices.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19995387" id="rid101" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          102 : Von Willebrand disease, angiodysplasia and atorvastatin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18510690" id="rid102" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          103 : Von Willebrand disease and angiodysplasia responding to atorvastatin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34060212" id="rid103" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          104 : Vascular abnormalities in patients with von Willebrand disease: A scoping review.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
